Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43861   clinical trials with a EudraCT protocol, of which   7284   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    First-In-Human, Dose Escalating Safety Study of Tissue Factor Specific Antibody-Drug Conjugate Tisotumab Vedotin (Humax®-TF-ADC) in Patients with Locally Advanced and/or Metastatic Solid Tumors Known to Express Tissue Factor

    Summary
    EudraCT number
    		 2013-001074-15
    Trial protocol
    		 GB  
    Global end of trial date
    02 May 2019

    Results information
    Results version number
    		 v1(current)
    This version publication date
    28 Apr 2021
    First version publication date
    28 Apr 2021
    Other versions

    Trial information

    		 Close Top of page
    Trial identification
    Sponsor protocol code
    GEN701
    Additional study identifiers
    ISRCTN number
    		 -
    US NCT number
    		 NCT02001623
    WHO universal trial number (UTN)
    		 -
    Sponsors
    Sponsor organisation name
    Genmab A/S
    Sponsor organisation address
    Kalvebod Brygge 43, Copenhagen, Denmark, DK-1560
    Public contact
    Clinical Trial Information, Genmab A/S, +45 70202728, clinicaltrials@genmab.com
    Scientific contact
    Clinical Trial Information, Genmab A/S, +45 70202728, clinicaltrials@genmab.com
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    02 May 2019
    Is this the analysis of the primary completion data?
    No
    Global end of trial reached?
    Yes
    Global end of trial date
    02 May 2019
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    The main objective of the trial was to establish the tolerability of tisotumab vedotin in a mixed population of participants with specified solid tumors.
    Protection of trial subjects
    The trial was conducted in accordance with the protocol and amendments, the International Council for Harmonisation E6 guideline for Good Clinical Practice, applicable local regulations, and ethical principles that have their origins in the Declaration of Helsinki. In addition, the trial was conducted in accordance with FDA 21 Code of Federal Regulations parts 312, 50, and 56, and the directive 2001/20/EC of the European Parliament.
    Background therapy
    		 -
    Evidence for comparator
    		 -
    Actual start date of recruitment
    02 Dec 2013
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    Yes
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    United States: 33
    Country: Number of subjects enrolled
    Belgium: 35
    Country: Number of subjects enrolled
    Denmark: 29
    Country: Number of subjects enrolled
    Sweden: 6
    Country: Number of subjects enrolled
    United Kingdom: 92
    Worldwide total number of subjects
    195
    EEA total number of subjects
    70
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    138
    From 65 to 84 years
    57
    85 years and over
    0

    Subject disposition

    		 Close Top of page
    Recruitment
    Recruitment details
    		 -

    Pre-assignment
    Screening details
    		 In the dose escalation part of the study, 40 participants were screened and 27 were enrolled and received treatment. In the dose expansion part of the study, 294 participants were screened and 168 were enrolled and received treatment.

    Period 1
    Period 1 title
    Overall Study (overall period)
    Is this the baseline period?
    		 Yes
    Allocation method
    Non-randomised - controlled
    Blinding used
    		 Not blinded

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    		 Dose Escalation Part
    Arm description
    		 Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days; 1Q3W) for four cycles (12 weeks total). After four cycles, if there was evidence of the participant benefiting from treatment, at the discretion of the treating physician, there was an option to continue in the study for up to a maximum of eight additional cycles (24 weeks) or until unacceptable toxicity was observed (maximum treatment duration: 36 weeks total).
    Arm type
    		 Experimental

    Investigational medicinal product name
    Tisotumab Vedotin
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Infusion
    Routes of administration
    Intravenous use
    Dosage and administration details
    Tisotumab vedotin was administered as an intravenous (IV) infusion at doses 0.3, 0.6, 0.9, 1.2, 1.5, 1.8, 2.0 and 2.2 mg/kg.

    Arm title
    		 Dose Expansion Part
    Arm description
    		 Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days; 1Q3W) for four cycles (12 weeks total). After four cycles, if there was evidence of the participant benefiting from treatment, at the discretion of the treating physician, there was an option to continue in the study for up to a maximum of eight additional cycles (24 weeks) or until unacceptable toxicity was observed (maximum treatment duration: 36 weeks total).
    Arm type
    		 Experimental

    Investigational medicinal product name
    Tisotumab Vedotin
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Infusion
    Routes of administration
    Intravenous use
    Dosage and administration details
    Tisotumab vedotin was administered as an IV infusion at a dose of 2.0 mg/kg.

    Number of subjects in period 1
    		Dose Escalation Part Dose Expansion Part
    Started
    27
    168
    Completed 4 cycles of treatment
    9
    81
    Completed 12 cycles of treatment
    2
    5
    Completed
    2
    5
    Not completed
    25
    163
         Adverse event, serious fatal
    1
    -
         Consent withdrawn by subject
    1
    16
         Physician decision
    -
    18
         Adverse event, non-fatal
    3
    35
         Dose limiting toxicity
    1
    -
         Other - miscellaneous
    -
    1
         Lost to follow-up
    -
    1
         Disease Progression
    19
    92

    Baseline characteristics

    		 Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Dose Escalation Part
    Reporting group description
    		 Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days; 1Q3W) for four cycles (12 weeks total). After four cycles, if there was evidence of the participant benefiting from treatment, at the discretion of the treating physician, there was an option to continue in the study for up to a maximum of eight additional cycles (24 weeks) or until unacceptable toxicity was observed (maximum treatment duration: 36 weeks total).

    Reporting group title
    Dose Expansion Part
    Reporting group description
    		 Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days; 1Q3W) for four cycles (12 weeks total). After four cycles, if there was evidence of the participant benefiting from treatment, at the discretion of the treating physician, there was an option to continue in the study for up to a maximum of eight additional cycles (24 weeks) or until unacceptable toxicity was observed (maximum treatment duration: 36 weeks total).

    Reporting group values
    		 Dose Escalation Part Dose Expansion Part Total
    Number of subjects
    		 27 168 195
    Age categorical
    Units: Subjects
        In utero
    		 0 0 0
        Preterm newborn infants (gestational age < 37 wks)
    		 0 0 0
        Newborns (0-27 days)
    		 0 0 0
        Infants and toddlers (28 days-23 months)
    		 0 0 0
        Children (2-11 years)
    		 0 0 0
        Adolescents (12-17 years)
    		 0 0 0
        Adults (18-64 years)
    		 20 118 138
        From 65-84 years
    		 7 50 57
        85 years and over
    		 0 0 0
    Age continuous
    Units: years
        median (full range (min-max))
    		 62 (43 to 73) 58 (21 to 79) -
    Gender categorical
    Units: Subjects
        Female
    		 18 122 140
        Male
    		 9 46 55
    Race
    Units: Subjects
        White
    		 27 155 182
        Black or African American
    		 0 2 2
        Asian
    		 0 5 5
        Native Hawaiian or other Pacific Islander
    		 0 1 1
        Other
    		 0 2 2
        Missing
    		 0 3 3
    Ethnicity
    Units: Subjects
        Hispanic or Latino
    		 0 2 2
        Not Hispanic or Latino
    		 27 164 191
        Missing
    		 0 2 2

    End points

    		 Close Top of page
    End points reporting groups
    Reporting group title
    Dose Escalation Part
    Reporting group description
    		 Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days; 1Q3W) for four cycles (12 weeks total). After four cycles, if there was evidence of the participant benefiting from treatment, at the discretion of the treating physician, there was an option to continue in the study for up to a maximum of eight additional cycles (24 weeks) or until unacceptable toxicity was observed (maximum treatment duration: 36 weeks total).

    Reporting group title
    Dose Expansion Part
    Reporting group description
    		 Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days; 1Q3W) for four cycles (12 weeks total). After four cycles, if there was evidence of the participant benefiting from treatment, at the discretion of the treating physician, there was an option to continue in the study for up to a maximum of eight additional cycles (24 weeks) or until unacceptable toxicity was observed (maximum treatment duration: 36 weeks total).

    Subject analysis set title
    Dose Escalation Part: 0.3 mg/kg
    Subject analysis set type
    		 Sub-group analysis
    Subject analysis set description
    Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 0.3 mg/kg of body weight.

    Subject analysis set title
    Dose Escalation Part: 0.6 mg/kg
    Subject analysis set type
    		 Sub-group analysis
    Subject analysis set description
    Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 0.6 mg/kg of body weight.

    Subject analysis set title
    Dose Escalation Part: 0.9 mg/kg
    Subject analysis set type
    		 Sub-group analysis
    Subject analysis set description
    Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 0.9 mg/kg of body weight.

    Subject analysis set title
    Dose Escalation Part: 1.2 mg/kg
    Subject analysis set type
    		 Sub-group analysis
    Subject analysis set description
    Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 1.2 mg/kg of body weight.

    Subject analysis set title
    Dose Escalation Part: 1.5 mg/kg
    Subject analysis set type
    		 Sub-group analysis
    Subject analysis set description
    Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 1.5 mg/kg of body weight.

    Subject analysis set title
    Dose Escalation Part: 1.8 mg/kg
    Subject analysis set type
    		 Sub-group analysis
    Subject analysis set description
    Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 1.8 mg/kg of body weight.

    Subject analysis set title
    Dose Escalation Part: 2.0 mg/kg
    Subject analysis set type
    		 Sub-group analysis
    Subject analysis set description
    Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.

    Subject analysis set title
    Dose Escalation Part: 2.2 mg/kg
    Subject analysis set type
    		 Sub-group analysis
    Subject analysis set description
    Participants received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.2 mg/kg of body weight.

    Subject analysis set title
    Dose Expansion Part: Bladder Cancer
    Subject analysis set type
    		 Sub-group analysis
    Subject analysis set description
    Participants with bladder cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.

    Subject analysis set title
    Dose Expansion Part: Cervical Cancer
    Subject analysis set type
    		 Sub-group analysis
    Subject analysis set description
    Participants with cervical cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.

    Subject analysis set title
    Dose Expansion Part: Endometrial Cancer
    Subject analysis set type
    		 Sub-group analysis
    Subject analysis set description
    Participants with endometrial cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.

    Subject analysis set title
    Dose Expansion Part: Esophageal Cancer
    Subject analysis set type
    		 Sub-group analysis
    Subject analysis set description
    Participants with esophageal cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.

    Subject analysis set title
    Dose Expansion Part: Non-Small Cell Lung Cancer (NSCLC)
    Subject analysis set type
    		 Sub-group analysis
    Subject analysis set description
    Participants with NSCLC received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.

    Subject analysis set title
    Dose Expansion Part: Ovarian Cancer
    Subject analysis set type
    		 Sub-group analysis
    Subject analysis set description
    Participants with ovarian cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.

    Subject analysis set title
    Dose Expansion Part: Prostate Cancer
    Subject analysis set type
    		 Sub-group analysis
    Subject analysis set description
    Participants with prostate cancer received tisotumab vedotin on Day 1 of each cycle (each treatment cycle was 21 days) as an IV infusion at a dose of 2.0 mg/kg of body weight.

    Subject analysis set title
    Dose Expansion Part: Pharmacokinetics (PK) Analysis Set
    Subject analysis set type
    		 Sub-group analysis
    Subject analysis set description
    The PK analysis set includes all participants in the dose expansion who had been exposed to tisotumab vedotin and had at least one PK assessment after the first dose.

    Primary: Dose Escalation Part: Evaluation of Treatment-Emergent Adverse Events

    		 Close Top of page
    End point title
    		 Dose Escalation Part: Evaluation of Treatment-Emergent Adverse Events [1]
    End point description
    Evaluation of treatment-emergent adverse events (AEs) includes number of participants with at least one: AE Serious adverse event (SAE) Infusion-related AE Common Terminology Criteria for Adverse Events (CTCAE) grade >=3 Treatment-related AE
    End point type
    Primary
    End point timeframe
    Treatment emergent adverse events are reported from Day 1 to 30 days after dosing. The exposure ranged from 1 to 249 days in the escalation part.
    Notes
    [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: Only summary statistics were planned for this endpoint
    End point values
    		 Dose Escalation Part: 0.3 mg/kg Dose Escalation Part: 0.6 mg/kg Dose Escalation Part: 0.9 mg/kg Dose Escalation Part: 1.2 mg/kg Dose Escalation Part: 1.5 mg/kg Dose Escalation Part: 1.8 mg/kg Dose Escalation Part: 2.0 mg/kg Dose Escalation Part: 2.2 mg/kg
    Number of subjects analysed
    3
    3
    3
    3
    3
    3
    3
    6
    Units: Participants
        AEs
    3
    3
    3
    3
    3
    3
    3
    6
        SAEs
    2
    1
    0
    2
    2
    2
    2
    4
        Infusion-Related AEs
    1
    0
    0
    0
    0
    0
    0
    0
        CTCAE Grade >=3 AEs
    2
    3
    1
    1
    2
    3
    2
    4
        AEs Related to Study Drug
    3
    3
    2
    3
    3
    3
    3
    6
    No statistical analyses for this end point

    Primary: Dose Expansion Part: Evaluation of Treatment-Emergent Adverse Events

    		 Close Top of page
    End point title
    		 Dose Expansion Part: Evaluation of Treatment-Emergent Adverse Events [2]
    End point description
    Evaluation of treatment-emergent adverse events (AEs) includes number of participants with at least one: AE Serious adverse event (SAE) Infusion-related AE Common terminology criteria for adverse events (CTCAE) grade >=3 Treatment-related AE
    End point type
    Primary
    End point timeframe
    Treatment emergent adverse events are reported from Day 1 to 30 days after dosing. The exposure ranged from 1 to 325 days in the expansion part.
    Notes
    [2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: Only summary statistics were planned for this endpoint
    End point values
    		 Dose Expansion Part: Bladder Cancer Dose Expansion Part: Cervical Cancer Dose Expansion Part: Endometrial Cancer Dose Expansion Part: Esophageal Cancer Dose Expansion Part: Non-Small Cell Lung Cancer (NSCLC) Dose Expansion Part: Ovarian Cancer Dose Expansion Part: Prostate Cancer
    Number of subjects analysed
    15
    55
    14
    15
    15
    36
    18
    Units: Participants
        AEs
    15
    55
    14
    15
    15
    36
    18
        SAEs
    7
    26
    5
    8
    6
    13
    6
        Infusion-Related AEs
    1
    1
    1
    1
    2
    0
    0
        CTCAE Grade >=3 AEs
    9
    30
    8
    8
    10
    16
    11
        AEs Related to Study Drug
    15
    54
    13
    14
    14
    36
    18
    No statistical analyses for this end point

    Secondary: Dose Escalation and Expansion Part: Number of Participants with Markedly Abnormal Hematology Values

    		 Close Top of page
    End point title
    		 Dose Escalation and Expansion Part: Number of Participants with Markedly Abnormal Hematology Values
    End point description
    Number of participants with markedly abnormal hematology results were defined as all participants who experienced at least 1 CTCAE grade >= 3 hematology value.
    End point type
    Secondary
    End point timeframe
    Day 1 to end of follow-up, up to a maximum of 60 weeks
    End point values
    		 Dose Escalation Part: 0.3 mg/kg Dose Escalation Part: 0.6 mg/kg Dose Escalation Part: 0.9 mg/kg Dose Escalation Part: 1.2 mg/kg Dose Escalation Part: 1.5 mg/kg Dose Escalation Part: 1.8 mg/kg Dose Escalation Part: 2.0 mg/kg Dose Escalation Part: 2.2 mg/kg Dose Expansion Part: Bladder Cancer Dose Expansion Part: Cervical Cancer Dose Expansion Part: Endometrial Cancer Dose Expansion Part: Esophageal Cancer Dose Expansion Part: Non-Small Cell Lung Cancer (NSCLC) Dose Expansion Part: Ovarian Cancer Dose Expansion Part: Prostate Cancer
    Number of subjects analysed
    3
    3
    3
    3
    3
    3
    3
    6
    15
    55
    14
    15
    15
    36
    18
    Units: participants
    2
    1
    1
    0
    2
    2
    0
    1
    0
    23
    0
    3
    1
    5
    3
    No statistical analyses for this end point

    Secondary: Dose Escalation and Expansion Parts: Number of Participants with Markedly Abnormal Coagulation Values

    		 Close Top of page
    End point title
    		 Dose Escalation and Expansion Parts: Number of Participants with Markedly Abnormal Coagulation Values
    End point description
    Number of participants with markedly abnormal coagulation results were defined as all participants who experienced at least 1 CTCAE grade >= 3 coagulation value.
    End point type
    Secondary
    End point timeframe
    Day 1 to end of follow-up, up to a maximum of 60 weeks
    End point values
    		 Dose Escalation Part: 0.3 mg/kg Dose Escalation Part: 0.6 mg/kg Dose Escalation Part: 0.9 mg/kg Dose Escalation Part: 1.2 mg/kg Dose Escalation Part: 1.5 mg/kg Dose Escalation Part: 1.8 mg/kg Dose Escalation Part: 2.0 mg/kg Dose Escalation Part: 2.2 mg/kg Dose Expansion Part: Bladder Cancer Dose Expansion Part: Cervical Cancer Dose Expansion Part: Endometrial Cancer Dose Expansion Part: Esophageal Cancer Dose Expansion Part: Non-Small Cell Lung Cancer (NSCLC) Dose Expansion Part: Ovarian Cancer Dose Expansion Part: Prostate Cancer
    Number of subjects analysed
    3
    3
    3
    3
    3
    3
    3
    6
    15
    55
    14
    15
    15
    36
    18
    Units: participants
    0
    0
    0
    0
    0
    0
    0
    1
    1
    7
    2
    0
    2
    5
    4
    No statistical analyses for this end point

    Secondary: Dose Escalation and Expansion Part: Number of Participants with Markedly Abnormal Biochemistry Values

    		 Close Top of page
    End point title
    		 Dose Escalation and Expansion Part: Number of Participants with Markedly Abnormal Biochemistry Values
    End point description
    Number of participants with markedly abnormal biochemistry results were defined as all participants who experienced at least 1 CTCAE grade >= 3 biochemistry value.
    End point type
    Secondary
    End point timeframe
    Day 1 to end of follow-up, up to a maximum of 60 weeks
    End point values
    		 Dose Escalation Part: 0.3 mg/kg Dose Escalation Part: 0.6 mg/kg Dose Escalation Part: 0.9 mg/kg Dose Escalation Part: 1.2 mg/kg Dose Escalation Part: 1.5 mg/kg Dose Escalation Part: 1.8 mg/kg Dose Escalation Part: 2.0 mg/kg Dose Escalation Part: 2.2 mg/kg Dose Expansion Part: Bladder Cancer Dose Expansion Part: Cervical Cancer Dose Expansion Part: Endometrial Cancer Dose Expansion Part: Esophageal Cancer Dose Expansion Part: Non-Small Cell Lung Cancer (NSCLC) Dose Expansion Part: Ovarian Cancer Dose Expansion Part: Prostate Cancer
    Number of subjects analysed
    3
    3
    3
    3
    3
    3
    3
    6
    15
    55
    14
    15
    15
    36
    18
    Units: participants
    2
    1
    3
    0
    1
    0
    1
    2
    4
    8
    4
    6
    2
    9
    4
    No statistical analyses for this end point

    Secondary: Dose Escalation and Expansion Parts: Number of Participants Who Experienced a Skin Rash

    		 Close Top of page
    End point title
    		 Dose Escalation and Expansion Parts: Number of Participants Who Experienced a Skin Rash
    End point description
    End point type
    Secondary
    End point timeframe
    Day 1 to end of follow-up, up to a maximum of 60 weeks
    End point values
    		 Dose Escalation Part: 0.3 mg/kg Dose Escalation Part: 0.6 mg/kg Dose Escalation Part: 0.9 mg/kg Dose Escalation Part: 1.2 mg/kg Dose Escalation Part: 1.5 mg/kg Dose Escalation Part: 1.8 mg/kg Dose Escalation Part: 2.0 mg/kg Dose Escalation Part: 2.2 mg/kg Dose Expansion Part: Bladder Cancer Dose Expansion Part: Cervical Cancer Dose Expansion Part: Endometrial Cancer Dose Expansion Part: Esophageal Cancer Dose Expansion Part: Non-Small Cell Lung Cancer (NSCLC) Dose Expansion Part: Ovarian Cancer Dose Expansion Part: Prostate Cancer
    Number of subjects analysed
    3
    3
    3
    3
    3
    3
    3
    6
    15
    55
    14
    15
    15
    36
    18
    Units: Participants
    1
    0
    0
    2
    0
    2
    2
    4
    3
    6
    2
    2
    2
    8
    5
    No statistical analyses for this end point

    Secondary: Dose Escalation and Expansion Parts: Number of Participants Who Experienced a Bleeding Event

    		 Close Top of page
    End point title
    		 Dose Escalation and Expansion Parts: Number of Participants Who Experienced a Bleeding Event
    End point description
    Bleeding adverse events of special interest included treatment emergent adverse events with preferred terms within the following standardised MedDRA queries: Haemorrhage terms, excluding laboratory terms SMQ [20000039] (Broad) and Haemorrhage, laboratory terms SMQ [20000040] (Narrow). Bleeding adverse events of special interest were evaluated according to the Common Terminology Criteria for Adverse Events (CTCAE) and were graded from 1 to 5, where 1 indicated a mild event and 5 indicated a fatal event. Bleeding events of all grades are included in the numbers below.
    End point type
    Secondary
    End point timeframe
    Day 1 to end of follow-up, up to a maximum of 60 weeks
    End point values
    		 Dose Escalation Part: 0.3 mg/kg Dose Escalation Part: 0.6 mg/kg Dose Escalation Part: 0.9 mg/kg Dose Escalation Part: 1.2 mg/kg Dose Escalation Part: 1.5 mg/kg Dose Escalation Part: 1.8 mg/kg Dose Escalation Part: 2.0 mg/kg Dose Escalation Part: 2.2 mg/kg Dose Expansion Part: Bladder Cancer Dose Expansion Part: Cervical Cancer Dose Expansion Part: Endometrial Cancer Dose Expansion Part: Esophageal Cancer Dose Expansion Part: Non-Small Cell Lung Cancer (NSCLC) Dose Expansion Part: Ovarian Cancer Dose Expansion Part: Prostate Cancer
    Number of subjects analysed
    3
    3
    3
    3
    3
    3
    3
    6
    15
    55
    14
    15
    15
    36
    18
    Units: Participants
    0
    1
    0
    3
    3
    3
    2
    5
    10
    31
    10
    7
    9
    27
    10
    No statistical analyses for this end point

    Secondary: Dose Escalation and Expansion Part: Number of Participants Who Experienced a Neuropathy Event

    		 Close Top of page
    End point title
    		 Dose Escalation and Expansion Part: Number of Participants Who Experienced a Neuropathy Event
    End point description
    Peripheral neuropathy events of special interest were evaluated according to the Common Terminology Criteria for Adverse Events (CTCAE) and were graded from 1 to 5, where 1 indicated a mild event and 5 indicated a fatal event. Peripheral neuropathy events of all grades are included in the numbers below.
    End point type
    Secondary
    End point timeframe
    Day 1 to end of follow-up, up to a maximum of 60 weeks
    End point values
    		 Dose Escalation Part: 0.3 mg/kg Dose Escalation Part: 0.6 mg/kg Dose Escalation Part: 0.9 mg/kg Dose Escalation Part: 1.2 mg/kg Dose Escalation Part: 1.5 mg/kg Dose Escalation Part: 1.8 mg/kg Dose Escalation Part: 2.0 mg/kg Dose Escalation Part: 2.2 mg/kg Dose Expansion Part: Bladder Cancer Dose Expansion Part: Cervical Cancer Dose Expansion Part: Endometrial Cancer Dose Expansion Part: Esophageal Cancer Dose Expansion Part: Non-Small Cell Lung Cancer (NSCLC) Dose Expansion Part: Ovarian Cancer Dose Expansion Part: Prostate Cancer
    Number of subjects analysed
    3
    3
    3
    3
    3
    3
    3
    6
    15
    55
    14
    15
    15
    36
    18
    Units: Participants
    0
    1
    1
    1
    0
    1
    0
    1
    5
    17
    6
    3
    5
    17
    7
    No statistical analyses for this end point

    Secondary: Dose Escalation Part: Clearance of Tisotumab Vedotin and Total HuMax-TF

    		 Close Top of page
    End point title
    		 Dose Escalation Part: Clearance of Tisotumab Vedotin and Total HuMax-TF
    End point description
    PK parameters in plasma were determined based on non-compartmental methods and calculated separately for Cycle 1 and Cycle 2 in each part of the study. Data was not planned to be collected for the clearance of tisotumab vedotin and total HuMax-TF. 99999 = no evaluable data. 99999 is presented when no participants had evaluable data or only 1 participant had evaluable data, so geometric coefficient of variation could not be calculated.
    End point type
    Secondary
    End point timeframe
    Before infusion, Day 1 (pre-dose) and 0.25 to 336 hours post-dose of Cycle 1 and Cycle 2 (each cycle was 21 days)
    End point values
    		 Dose Escalation Part: 0.3 mg/kg Dose Escalation Part: 0.6 mg/kg Dose Escalation Part: 0.9 mg/kg Dose Escalation Part: 1.2 mg/kg Dose Escalation Part: 1.5 mg/kg Dose Escalation Part: 1.8 mg/kg Dose Escalation Part: 2.0 mg/kg Dose Escalation Part: 2.2 mg/kg
    Number of subjects analysed
    0 [3]
    3 [4]
    3
    3
    3
    3 [5]
    3 [6]
    5 [7]
    Units: mL/hr/kg
    geometric mean (geometric coefficient of variation)
        Tisotumab Vedotin: Cycle 1
    ±
    1.61 ± 7.79
    1.46 ± 15.23
    1.07 ± 11.60
    1.84 ± 20.59
    1.17 ± 60.05
    1.56 ± 34.12
    0.87 ± 8.93
        Tisotumab Vedotin: Cycle 2
    ±
    1.72 ± 4.98
    1.44 ± 6.32
    1.07 ± 10.45
    2.05 ± 26.80
    0.93 ± 24.03
    1.30 ± 19.06
    1.03 ± 11.34
        Total HuMax-TF: Cycle 1
    ±
    1.02 ± 0.20
    0.98 ± 16.90
    0.69 ± 12.61
    1.26 ± 31.29
    0.81 ± 69.72
    0.87 ± 33.85
    0.56 ± 14.13
        Total HuMax-TF: Cycle 2
    ±
    1.05 ± 9.95
    0.98 ± 6.52
    0.71 ± 13.41
    1.40 ± 31.39
    0.53 ± 12.41
    0.82 ± 26.45
    0.61 ± 9.72
    Notes
    [3] - No evaluable PK assessments
    [4] - Tisotumab Vedotin Cycle 2 N = 2 Total HuMax-TF Cycle 1 N = 2 Total HuMax-TF Cycle 2 N = 2
    [5] - Tisotumab Vedotin Cycle 2 N = 2 Total HuMax-TF Cycle 2 N = 2
    [6] - Tisotumab Vedotin Cycle 2 N = 2 Total HuMax-TF Cycle 2 N = 2
    [7] - Tisotumab Vedotin Cycle 2 N = 3 Total HuMax-TF Cycle 2 N = 3
    No statistical analyses for this end point

    Secondary: Dose Escalation Part: Volume of Distribution of Tisotumab Vedotin and Total HuMax-TF

    		 Close Top of page
    End point title
    		 Dose Escalation Part: Volume of Distribution of Tisotumab Vedotin and Total HuMax-TF
    End point description
    PK parameters in plasma were determined based on non-compartmental methods and calculated separately for Cycle 1 and Cycle 2 in each part of the study. Data was not planned to be collected for the volume of distribution of tisotumab vedotin and total HuMax-TF for the dose expansion part. 99999 = no evaluable data. 99999 is presented when no participants had evaluable data or only 1 participant had evaluable data, so geometric coefficient of variation could not be calculated.
    End point type
    Secondary
    End point timeframe
    Before infusion, Day 1 (pre-dose) and 0.25 to 336 hours post-dose of Cycle 1 and Cycle 2 (each cycle was 21 days)
    End point values
    		 Dose Escalation Part: 0.3 mg/kg Dose Escalation Part: 0.6 mg/kg Dose Escalation Part: 0.9 mg/kg Dose Escalation Part: 1.2 mg/kg Dose Escalation Part: 1.5 mg/kg Dose Escalation Part: 1.8 mg/kg Dose Escalation Part: 2.0 mg/kg Dose Escalation Part: 2.2 mg/kg
    Number of subjects analysed
    0 [8]
    3 [9]
    3
    3
    3
    3 [10]
    3 [11]
    5 [12]
    Units: mL/kg
    geometric mean (geometric coefficient of variation)
        Tisotumab Vedotin: Cycle 1
    ±
    68.40 ± 11.84
    70.80 ± 14.54
    63.46 ± 16.87
    86.10 ± 12.38
    81.13 ± 35.60
    92.04 ± 21.62
    61.46 ± 18.07
        Tisotumab Vedotin: Cycle 2
    ±
    76.69 ± 9.53
    69.74 ± 7.99
    62.61 ± 6.03
    99.20 ± 20.82
    70.21 ± 42.93
    74.82 ± 4.19
    72.74 ± 5.79
        Total HuMax-TF: Cycle 1
    ±
    51.55 ± 1.61
    60.27 ± 17.79
    57.38 ± 8.65
    77.55 ± 10.74
    67.26 ± 50.61
    68.69 ± 30.52
    50.69 ± 7.20
        Total HuMax-TF: Cycle 2
    ±
    55.75 ± 10.80
    57.13 ± 8.90
    58.48 ± 12.66
    84.98 ± 22.85
    50.62 ± 36.02
    60.40 ± 17.48
    58.10 ± 12.31
    Notes
    [8] - Not calculated where the percentage of the AUC that is due to the extrapolation is more than 20%.
    [9] - Tisotumab Vedotin Cycle 2 N = 2 Total HuMax-TF Cycle 1 N = 2 Total HuMax-TF Cycle 2 N = 2
    [10] - Tisotumab Vedotin Cycle 2 N = 2 Total HuMax-TF Cycle 2 N = 2
    [11] - Tisotumab Vedotin Cycle 2 N = 2 Total HuMax-TF Cycle 2 N = 2
    [12] - Tisotumab Vedotin Cycle 2 N = 3 Total HuMax-TF Cycle 2 N = 3
    No statistical analyses for this end point

    Secondary: Dose Escalation and Expansion Part: Area Under the Curve from Time Zero to the Last Measurable Concentration (AUC0-t) of Tisotumab Vedotin and Total HuMax-TF

    		 Close Top of page
    End point title
    		 Dose Escalation and Expansion Part: Area Under the Curve from Time Zero to the Last Measurable Concentration (AUC0-t) of Tisotumab Vedotin and Total HuMax-TF
    End point description
    PK parameters in plasma were determined based on non-compartmental methods and calculated separately for Cycle 1 and Cycle 2 in each part of the study.
    End point type
    Secondary
    End point timeframe
    Before infusion, Day 1 (pre-dose) and 0.25 to 336 hours post-dose of Cycle 1 and Cycle 2 (each cycle was 21 days)
    End point values
    		 Dose Escalation Part: 0.3 mg/kg Dose Escalation Part: 0.6 mg/kg Dose Escalation Part: 0.9 mg/kg Dose Escalation Part: 1.2 mg/kg Dose Escalation Part: 1.5 mg/kg Dose Escalation Part: 1.8 mg/kg Dose Escalation Part: 2.0 mg/kg Dose Escalation Part: 2.2 mg/kg Dose Expansion Part: Pharmacokinetics (PK) Analysis Set
    Number of subjects analysed
    3
    3
    3
    3
    3
    3
    3 [13]
    6 [14]
    168 [15]
    Units: day*ug/mL
    geometric mean (geometric coefficient of variation)
        Tisotumab Vedotin: Cycle 1
    2.5 ± 3.1
    15.4 ± 8.2
    25.1 ± 16.9
    45.2 ± 9.3
    33.1 ± 19.0
    63.0 ± 49.3
    52.3 ± 33.1
    84.9 ± 33.7
    79.31 ± 49.40
        Tisotumab Vedotin: Cycle 2
    2.0 ± 15.7
    9.9 ± 49.1
    25.6 ± 7.1
    45.2 ± 10.1
    29.8 ± 25.1
    42.7 ± 72.7
    62.7 ± 21.5
    86.3 ± 14.4
    68.54 ± 55.49
        Total HuMax-TF: Cycle 1
    2.9 ± 0.5
    15.4 ± 53.1
    35.0 ± 18.9
    60.4 ± 13.4
    44.9 ± 27.8
    86.7 ± 54.3
    85.9 ± 36.7
    123.0 ± 34.7
    112.70 ± 45.23
        Total HuMax-TF: Cycle 2
    2.4 ± 12.3
    14.4 ± 55.4
    35.7 ± 7.1
    58.8 ± 15.5
    40.9 ± 26.2
    60.2 ± 76.6
    92.5 ± 33.4
    133.6 ± 13.9
    114.54 ± 45.83
    Notes
    [13] - Tisotumab Vedotin Cycle 2 N = 2 Total HuMax-TF Cycle 2 N = 2
    [14] - Tisotumab Vedotin Cycle 2 N = 3 Total HuMax-TF Cycle 2 N = 3
    [15] - Tisotumab Vedotin Cycle 1 N = 167 Tisotumab Vedotin Cycle 2 N = 146 HuMax-TF Cycle 2 N = 146
    No statistical analyses for this end point

    Secondary: Dose Escalation Part: Area Under the Curve from Time Zero Extrapolated to Infinity (AUC0-inf) of Tisotumab Vedotin and Total HuMax-TF

    		 Close Top of page
    End point title
    		 Dose Escalation Part: Area Under the Curve from Time Zero Extrapolated to Infinity (AUC0-inf) of Tisotumab Vedotin and Total HuMax-TF
    End point description
    PK parameters in plasma were determined based on non-compartmental methods and calculated separately for Cycle 1 and Cycle 2. AUC0-inf was only analyzed in the dose escalation part of the study. Data was not planned to be collected for the AUC0-inf of tisotumab vedotin and total HuMax-TF for the dose expansion part. 99999 = no evaluable data. 99999 is presented when no participants had evaluable data or only 1 participant had evaluable data, so geometric coefficient of variation could not be calculated.
    End point type
    Secondary
    End point timeframe
    Before infusion, Day 1 (pre-dose) and 0.25 to 336 hours post-dose of Cycle 1 and Cycle 2 (each cycle was 21 days)
    End point values
    		 Dose Escalation Part: 0.3 mg/kg Dose Escalation Part: 0.6 mg/kg Dose Escalation Part: 0.9 mg/kg Dose Escalation Part: 1.2 mg/kg Dose Escalation Part: 1.5 mg/kg Dose Escalation Part: 1.8 mg/kg Dose Escalation Part: 2.0 mg/kg Dose Escalation Part: 2.2 mg/kg
    Number of subjects analysed
    0 [16]
    3 [17]
    3
    3
    3
    3 [18]
    3 [19]
    5 [20]
    Units: day*ug/mL
    geometric mean (geometric coefficient of variation)
        Tisotumab Vedotin: Cycle 1
    ±
    15.57 ± 7.81
    25.77 ± 15.70
    46.68 ± 10.99
    33.95 ± 20.93
    63.88 ± 48.61
    53.47 ± 30.88
    105.84 ± 8.68
        Tisotumab Vedotin: Cycle 2
    ±
    14.52 ± 4.98
    26.12 ± 6.44
    46.59 ± 9.98
    30.56 ± 26.43
    80.59 ± 24.03
    64.10 ± 19.06
    88.95 ± 11.04
        Total HuMax-TF: Cycle 1
    ±
    23.75 ± 0.20
    37.02 ± 16.39
    69.96 ± 13.26
    48.19 ± 35.67
    90.08 ± 52.74
    93.29 ± 30.45
    157.81 ± 12.70
        Total HuMax-TF: Cycle 2
    ±
    23.01 ± 9.95
    37.08 ± 6.37
    67.93 ± 14.25
    43.41 ± 30.31
    136.08 ± 12.41
    98.59 ± 26.45
    145.82 ± 9.42
    Notes
    [16] - Not calculated where the percentage of the AUC that is due to the extrapolation is more than 20%.
    [17] - Total HuMax-TF Cycle 1 N = 2 Total HuMax-TF Cycle 2 N = 2
    [18] - Tisotumab Vedotin Cycle 2 N = 2 Total HuMax-TF Cycle 2 N = 2
    [19] - Tisotumab Vedotin Cycle 2 N = 2 Total HuMax-TF Cycle 2 N = 2
    [20] - Tisotumab Vedotin Cycle 2 N = 3 Total HuMax-TF Cycle 1 N = 2 Total HuMax-TF Cycle 2 N = 3
    No statistical analyses for this end point

    Secondary: Dose Escalation and Expansion Part: Maximum Observed Plasma Concentration (Cmax) of Tisotumab Vedotin and Total HuMax-TF

    		 Close Top of page
    End point title
    		 Dose Escalation and Expansion Part: Maximum Observed Plasma Concentration (Cmax) of Tisotumab Vedotin and Total HuMax-TF
    End point description
    PK parameters in plasma were determined based on non-compartmental methods and calculated separately for Cycle 1 and Cycle 2 in each part of the study.
    End point type
    Secondary
    End point timeframe
    Before infusion, Day 1 (pre-dose) and 0.25 to 336 hours post-dose of Cycle 1 and Cycle 2 (each cycle was 21 days)
    End point values
    		 Dose Escalation Part: 0.3 mg/kg Dose Escalation Part: 0.6 mg/kg Dose Escalation Part: 0.9 mg/kg Dose Escalation Part: 1.2 mg/kg Dose Escalation Part: 1.5 mg/kg Dose Escalation Part: 1.8 mg/kg Dose Escalation Part: 2.0 mg/kg Dose Escalation Part: 2.2 mg/kg Dose Expansion Part: Pharmacokinetics (PK) Analysis Set
    Number of subjects analysed
    3
    3
    3
    3
    3
    3
    3 [21]
    6 [22]
    168 [23]
    Units: ug/mL
    geometric mean (geometric coefficient of variation)
        Tisotumab Vedotin: Cycle 1
    4.78 ± 12.35
    12.20 ± 9.47
    19.81 ± 17.32
    34.67 ± 18.48
    23.12 ± 21.10
    35.42 ± 39.20
    32.30 ± 22.08
    55.53 ± 10.31
    29.1 ± 34.1
        Tisotumab Vedotin: Cycle 2
    3.85 ± 27.65
    12.51 ± 11.51
    20.25 ± 5.14
    32.38 ± 7.11
    21.84 ± 24.97
    35.92 ± 30.39
    44.30 ± 0.32
    48.79 ± 26.37
    26.1 ± 41.2
        Total HuMax-TF: Cycle 1
    4.90 ± 13.00
    11.84 ± 8.31
    17.98 ± 11.64
    29.30 ± 10.14
    23.55 ± 25.16
    30.57 ± 37.42
    38.78 ± 21.77
    58.02 ± 12.77
    39.8 ± 31.1
        Total HuMax-TF: Cycle 2
    3.96 ± 21.83
    11.54 ± 8.83
    16.90 ± 1.57
    31.33 ± 8.13
    22.11 ± 21.03
    37.71 ± 42.96
    43.40 ± 6.67
    53.67 ± 19.75
    38.3 ± 33.3
    Notes
    [21] - Tisotumab Vedotin Cycle 2 N = 2 Total HuMax-TF Cycle 2 N = 2
    [22] - Tisotumab Vedotin Cycle 2 N = 3 Total HuMax-TF Cycle 2 N = 3
    [23] - Tisotumab Vedotin Cycle 1 N = 167 Tisotumab Vedotin Cycle 1 N = 146 Total HuMax-TF Cycle 2 N = 146
    No statistical analyses for this end point

    Secondary: Dose Escalation and Expansion Part: Time of Cmax (Tmax) of Tisotumab Vedotin and Total HuMax-TF

    		 Close Top of page
    End point title
    		 Dose Escalation and Expansion Part: Time of Cmax (Tmax) of Tisotumab Vedotin and Total HuMax-TF
    End point description
    PK parameters in plasma were determined based on non-compartmental methods and calculated separately for Cycle 1 and Cycle 2 in each part of the study.
    End point type
    Secondary
    End point timeframe
    Before infusion, Day 1 (pre-dose) and 0.25 to 336 hours post-dose of Cycle 1 and Cycle 2 (each cycle was 21 days)
    End point values
    		 Dose Escalation Part: 0.3 mg/kg Dose Escalation Part: 0.6 mg/kg Dose Escalation Part: 0.9 mg/kg Dose Escalation Part: 1.2 mg/kg Dose Escalation Part: 1.5 mg/kg Dose Escalation Part: 1.8 mg/kg Dose Escalation Part: 2.0 mg/kg Dose Escalation Part: 2.2 mg/kg Dose Expansion Part: Pharmacokinetics (PK) Analysis Set
    Number of subjects analysed
    3
    3
    3
    3
    3
    3
    3 [24]
    6 [25]
    168 [26]
    Units: hours
    geometric mean (geometric coefficient of variation)
        Tisotumab Vedotin: Cycle 1
    1.47 ± 72.74
    1.18 ± 13.03
    1.34 ± 11.77
    1.15 ± 11.66
    1.12 ± 9.55
    1.18 ± 14.30
    1.18 ± 7.45
    1.11 ± 12.52
    1.21 ± 364.12
        Tisotumab Vedotin: Cycle 2
    1.54 ± 63.29
    1.34 ± 6.27
    1.32 ± 5.96
    1.13 ± 11.18
    1.21 ± 16.61
    2.44 ± 35.75
    1.14 ± 9.29
    1.29 ± 7.55
    1.44 ± 303.89
        Total HuMax-TF: Cycle 1
    2.20 ± 49.15
    1.18 ± 13.03
    1.34 ± 11.77
    1.15 ± 11.66
    1.12 ± 9.55
    1.18 ± 14.30
    1.18 ± 7.45
    1.11 ± 12.52
    1.10 ± 397.92
        Total HuMax-TF: Cycle 2
    2.19 ± 46.56
    1.34 ± 6.27
    1.32 ± 5.96
    1.13 ± 11.18
    1.21 ± 16.61
    1.76 ± 50.43
    1.14 ± 9.29
    1.29 ± 7.55
    1.15 ± 356.23
    Notes
    [24] - Tisotumab Vedotin Cycle 2 N = 2 Total HuMax-TF Cycle 2 N = 2
    [25] - Tisotumab Vedotin Cycle 2 N = 3 Total HuMax-TF Cycle 2 N = 3
    [26] - Tisotumab Vedotin Cycle 1 N = 167 Tisotumab Vedotin Cycle 2 N = 146 Total HuMax-TF Cycle 2 = 146
    No statistical analyses for this end point

    Secondary: Dose Escalation Part: Half-life (t1/2) of Tisotumab Vedotin and Total HuMax-TF

    		 Close Top of page
    End point title
    		 Dose Escalation Part: Half-life (t1/2) of Tisotumab Vedotin and Total HuMax-TF
    End point description
    PK parameters in plasma were determined based on non-compartmental methods and calculated separately for Cycle 1 and Cycle 2. T1/2 was determined only for the dose escalation part of the study. Data was not planned to be collected for t1/2 of tisotumab vedotin and total HuMax-TF for the dose expansion part per the study protocol.
    End point type
    Secondary
    End point timeframe
    Before infusion, Day 1 (pre-dose) and 0.25 to 336 hours post-dose of Cycle 1 and Cycle 2 (each cycle was 21 days)
    End point values
    		 Dose Escalation Part: 0.3 mg/kg Dose Escalation Part: 0.6 mg/kg Dose Escalation Part: 0.9 mg/kg Dose Escalation Part: 1.2 mg/kg Dose Escalation Part: 1.5 mg/kg Dose Escalation Part: 1.8 mg/kg Dose Escalation Part: 2.0 mg/kg Dose Escalation Part: 2.2 mg/kg
    Number of subjects analysed
    3
    3
    3
    3
    3
    3
    3 [27]
    6 [28]
    Units: hours
    geometric mean (geometric coefficient of variation)
        Tisotumab Vedotin: Cycle 1
    12.22 ± 11.61
    29.53 ± 4.08
    33.72 ± 6.26
    41.06 ± 6.85
    32.42 ± 20.05
    47.89 ± 25.82
    40.93 ± 11.48
    41.19 ± 34.02
        Tisotumab Vedotin: Cycle 2
    13.54 ± 5.50
    23.50 ± 39.89
    33.68 ± 1.74
    40.44 ± 4.69
    33.62 ± 14.50
    32.15 ± 62.74
    39.89 ± 23.15
    48.93 ± 5.61
        Total HuMax-TF: Cycle 1
    16.05 ± 27.93
    28.66 ± 30.64
    42.52 ± 7.48
    57.37 ± 8.65
    42.72 ± 34.62
    57.72 ± 17.47
    54.95 ± 5.32
    55.10 ± 27.36
        Total HuMax-TF: Cycle 2
    18.34 ± 8.73
    30.71 ± 27.65
    40.37 ± 4.27
    56.77 ± 9.60
    42.18 ± 25.39
    46.24 ± 53.11
    51.06 ± 9.18
    66.05 ± 10.07
    Notes
    [27] - Tisotumab Vedotin Cycle 2 N = 2 Total HuMax-TF Cycle 2 N = 2
    [28] - Tisotumab Vedotin Cycle 2 N = 3 Total HuMax-TF Cycle 2 N = 3
    No statistical analyses for this end point

    Secondary: Dose Escalation and Expansion Part: AUC0-t of Free Monomethyl Auristatin E (MMAE)

    		 Close Top of page
    End point title
    		 Dose Escalation and Expansion Part: AUC0-t of Free Monomethyl Auristatin E (MMAE)
    End point description
    PK parameters in plasma were determined based on non-compartmental methods and calculated separately for Cycle 1 and Cycle 2 in each part of the study.
    End point type
    Secondary
    End point timeframe
    Before infusion, Day 1 (pre-dose) and 0.25 to 336 hours post-dose of Cycle 1 and Cycle 2 (each cycle was 21 days)
    End point values
    		 Dose Escalation Part: 0.3 mg/kg Dose Escalation Part: 0.6 mg/kg Dose Escalation Part: 0.9 mg/kg Dose Escalation Part: 1.2 mg/kg Dose Escalation Part: 1.5 mg/kg Dose Escalation Part: 1.8 mg/kg Dose Escalation Part: 2.0 mg/kg Dose Escalation Part: 2.2 mg/kg Dose Expansion Part: Pharmacokinetics (PK) Analysis Set
    Number of subjects analysed
    3
    3
    3
    3
    3
    3
    3 [29]
    6 [30]
    168 [31]
    Units: day*ng/mL
    geometric mean (geometric coefficient of variation)
        Cycle 1
    6.20 ± 72.05
    12.61 ± 28.18
    12.22 ± 67.23
    11.63 ± 52.69
    26.55 ± 44.24
    22.55 ± 57.26
    67.42 ± 59.98
    26.47 ± 59.35
    25.80 ± 93.91
        Cycle 2
    3.19 ± 140.85
    4.69 ± 87.27
    14.89 ± 66.97
    16.92 ± 58.12
    21.51 ± 34.25
    18.97 ± 52.14
    36.20 ± 33.82
    37.50 ± 43.08
    23.48 ± 76.47
    Notes
    [29] - Cycle 2 N = 2
    [30] - Cycle 2 N = 3
    [31] - Cycle 2 N = 145
    No statistical analyses for this end point

    Secondary: Dose Escalation Part: AUC0-inf of Free MMAE

    		 Close Top of page
    End point title
    		 Dose Escalation Part: AUC0-inf of Free MMAE
    End point description
    PK parameters in plasma were determined based on non-compartmental methods and calculated separately for Cycle 1 and Cycle 2. AUC0-inf was not planned to be collected for the dose expansion part. AUC0-inf is not calculated where the percentage of the AUC that is due to the extrapolation is more than 20%. 99999 = no evaluable data. 99999 is presented when no participants had evaluable data or only 1 participant had evaluable data, so geometric coefficient of variation could not be calculated.
    End point type
    Secondary
    End point timeframe
    Before infusion, Day 1 (pre-dose) and 0.25 to 336 hours post-dose of Cycle 1 and Cycle 2 (each cycle was 21 days)
    End point values
    		 Dose Escalation Part: 0.3 mg/kg Dose Escalation Part: 0.6 mg/kg Dose Escalation Part: 0.9 mg/kg Dose Escalation Part: 1.2 mg/kg Dose Escalation Part: 1.5 mg/kg Dose Escalation Part: 1.8 mg/kg Dose Escalation Part: 2.0 mg/kg Dose Escalation Part: 2.2 mg/kg
    Number of subjects analysed
    2 [32]
    1 [33]
    2
    1
    2 [34]
    1
    1 [35]
    1
    Units: day*ng/mL
    geometric mean (geometric coefficient of variation)
        Cycle 1
    12.63 ± 12.44
    13.93 ± 99999
    16.32 ± 57.56
    20.39 ± 0
    27.08 ± 58.96
    25.29 ± 99999
    78.31 ± 99999
    63.03 ± 99999
        Cycle 2
    99999 ± 99999
    99999 ± 99999
    22.32 ± 43.62
    31.40 ± 99999
    31.43 ± 99999
    33.23 ± 99999
    99999 ± 99999
    58.95 ± 99999
    Notes
    [32] - Cycle 2 N = 0
    [33] - Cycle 2 N = 0
    [34] - Cycle 2 N = 1
    [35] - Cycle 2 N = 0
    No statistical analyses for this end point

    Secondary: Dose Escalation and Expansion Part: Cmax of Free MMAE

    		 Close Top of page
    End point title
    		 Dose Escalation and Expansion Part: Cmax of Free MMAE
    End point description
    PK parameters in plasma were determined based on non-compartmental methods and calculated separately for Cycle 1 and Cycle 2 in each part of the study.
    End point type
    Secondary
    End point timeframe
    Before infusion, Day 1 (pre-dose) and 0.25 to 336 hours post-dose of Cycle 1 and Cycle 2 (each cycle was 21 days)
    End point values
    		 Dose Escalation Part: 0.3 mg/kg Dose Escalation Part: 0.6 mg/kg Dose Escalation Part: 0.9 mg/kg Dose Escalation Part: 1.2 mg/kg Dose Escalation Part: 1.5 mg/kg Dose Escalation Part: 1.8 mg/kg Dose Escalation Part: 2.0 mg/kg Dose Escalation Part: 2.2 mg/kg Dose Expansion Part: Pharmacokinetics (PK) Analysis Set
    Number of subjects analysed
    3
    3
    3
    3
    3
    3
    3 [36]
    6 [37]
    168 [38]
    Units: ng/mL
    geometric mean (geometric coefficient of variation)
        Cycle 1
    0.760 ± 62.505
    1.673 ± 30.756
    1.524 ± 54.491
    1.410 ± 19.149
    2.807 ± 39.398
    2.587 ± 29.172
    6.351 ± 61.505
    4.877 ± 31.350
    3.16 ± 88.30
        Cycle 2
    1.091 ± 74.293
    1.342 ± 24.320
    2.059 ± 51.470
    2.243 ± 50.367
    2.718 ± 39.492
    2.035 ± 39.785
    3.369 ± 36.875
    4.704 ± 18.856
    2.73 ± 78.69
    Notes
    [36] - Cycle 2 N = 2
    [37] - Cycle 2 N = 3
    [38] - Cycle 2 N = 145
    No statistical analyses for this end point

    Secondary: Dose Escalation and Expansion Part: Tmax of Free MMAE

    		 Close Top of page
    End point title
    		 Dose Escalation and Expansion Part: Tmax of Free MMAE
    End point description
    PK parameters in plasma were determined based on non-compartmental methods and calculated separately for Cycle 1 and Cycle 2 in each part of the study.
    End point type
    Secondary
    End point timeframe
    Before infusion, Day 1 (pre-dose) and 0.25 to 336 hours post-dose of Cycle 1 and Cycle 2 (each cycle was 21 days)
    End point values
    		 Dose Escalation Part: 0.3 mg/kg Dose Escalation Part: 0.6 mg/kg Dose Escalation Part: 0.9 mg/kg Dose Escalation Part: 1.2 mg/kg Dose Escalation Part: 1.5 mg/kg Dose Escalation Part: 1.8 mg/kg Dose Escalation Part: 2.0 mg/kg Dose Escalation Part: 2.2 mg/kg Dose Expansion Part: Pharmacokinetics (PK) Analysis Set
    Number of subjects analysed
    3
    3
    3
    3
    3
    3
    3 [39]
    6 [40]
    168 [41]
    Units: hours
    geometric mean (geometric coefficient of variation)
        Cycle 1
    23.88 ± 4.41
    22.77 ± 16.56
    24.39 ± 7.72
    24.19 ± 5.52
    25.07 ± 0.68
    47.74 ± 114.28
    83.24 ± 67.57
    84.88 ± 61.54
    154.28 ± 54.214
        Cycle 2
    23.73 ± 5.78
    24.05 ± 8.48
    23.92 ± 13.04
    24.94 ± 1.48
    25.26 ± 0.76
    46.24 ± 112.48
    65.15 ± 104.61
    47.12 ± 112.10
    125.38 ± 31.21
    Notes
    [39] - Cycle 2 N = 2
    [40] - Cycle 2 N = 3
    [41] - Cycle 2 = 145
    No statistical analyses for this end point

    Secondary: Dose Escalation Part: PK Parameters, T 1/2 of Free MMAE

    		 Close Top of page
    End point title
    		 Dose Escalation Part: PK Parameters, T 1/2 of Free MMAE
    End point description
    PK parameters in plasma were determined based on non-compartmental methods and calculated separately for Cycle 1 and Cycle 2. T1/2 was determined only for the dose escalation part of the study.
    End point type
    Secondary
    End point timeframe
    Dose escalation part (Cycles 1 and 2): Screening, pre-dose Day 1 then 0.25, 2, 5, 12, 24, 168, 336 and 504 hours post-dose.
    End point values
    		 Dose Escalation Part: 0.3 mg/kg Dose Escalation Part: 0.6 mg/kg Dose Escalation Part: 0.9 mg/kg Dose Escalation Part: 1.2 mg/kg Dose Escalation Part: 1.5 mg/kg Dose Escalation Part: 1.8 mg/kg Dose Escalation Part: 2.0 mg/kg Dose Escalation Part: 2.2 mg/kg
    Number of subjects analysed
    2 [42]
    1 [43]
    2
    1
    2 [44]
    1
    1 [45]
    1
    Units: hours
    geometric mean (geometric coefficient of variation)
        Cycle 1
    95.15 ± 25.74
    69.34 ± 99999
    63.98 ± 2.24
    62.58 ± 99999
    63.65 ± 7.86
    78.90 ± 99999
    57.74 ± 99999
    68.47 ± 99999
        Cycle 2
    99999 ± 99999
    99999 ± 99999
    69.65 ± 3.86
    60.71 ± 99999
    70.20 ± 99999
    78.94 ± 99999
    99999 ± 99999
    63.92 ± 99999
    Notes
    [42] - Cycle 2 N = 0
    [43] - Cycle 2 N = 0
    [44] - Cycle 2 N = 1
    [45] - Cycle 2 N = 0
    No statistical analyses for this end point

    Secondary: Dose Escalation and Expansion Part: Number of Participants with Positive Anti-Drug Antibodies (ADAs) to Tisotumab Vedotin

    		 Close Top of page
    End point title
    		 Dose Escalation and Expansion Part: Number of Participants with Positive Anti-Drug Antibodies (ADAs) to Tisotumab Vedotin
    End point description
    Participants who met the criterion for positive ADAs on treatment were defined as participants who were negative at baseline and had at least one positive post-baseline result, or participants who were positive at baseline and had at least one post-baseline result with a titer higher than baseline.
    End point type
    Secondary
    End point timeframe
    Day 1 to end of follow-up, up to a maximum of 60 weeks
    End point values
    		 Dose Escalation Part: 0.3 mg/kg Dose Escalation Part: 0.6 mg/kg Dose Escalation Part: 0.9 mg/kg Dose Escalation Part: 1.2 mg/kg Dose Escalation Part: 1.5 mg/kg Dose Escalation Part: 1.8 mg/kg Dose Escalation Part: 2.0 mg/kg Dose Escalation Part: 2.2 mg/kg Dose Expansion Part: Bladder Cancer Dose Expansion Part: Cervical Cancer Dose Expansion Part: Endometrial Cancer Dose Expansion Part: Esophageal Cancer Dose Expansion Part: Non-Small Cell Lung Cancer (NSCLC) Dose Expansion Part: Ovarian Cancer Dose Expansion Part: Prostate Cancer
    Number of subjects analysed
    3
    3
    3
    3
    3
    3
    3
    3
    12
    49
    12
    13
    12
    33
    18
    Units: Participants
    0
    0
    0
    0
    0
    0
    0
    0
    1
    3
    0
    0
    1
    0
    1
    No statistical analyses for this end point

    Secondary: Dose Escalation Part: Anti-Tumor Activity Measured by Number of Participants Who Experienced Tumor Shrinkage

    		 Close Top of page
    End point title
    		 Dose Escalation Part: Anti-Tumor Activity Measured by Number of Participants Who Experienced Tumor Shrinkage
    End point description
    End point type
    Secondary
    End point timeframe
    Day 1 to end of follow-up, up to a maximum of 60 weeks
    End point values
    		 Dose Escalation Part: 0.3 mg/kg Dose Escalation Part: 0.6 mg/kg Dose Escalation Part: 0.9 mg/kg Dose Escalation Part: 1.2 mg/kg Dose Escalation Part: 1.5 mg/kg Dose Escalation Part: 1.8 mg/kg Dose Escalation Part: 2.0 mg/kg Dose Escalation Part: 2.2 mg/kg
    Number of subjects analysed
    3
    3
    3
    3
    3
    3
    3
    6
    Units: participants
    0
    0
    0
    1
    0
    2
    1
    3
    No statistical analyses for this end point

    Secondary: Dose Expansion Part: Anti-Tumor Activity Measured by Maximum Reduction in the Sum of Lesion Measurements

    		 Close Top of page
    End point title
    		 Dose Expansion Part: Anti-Tumor Activity Measured by Maximum Reduction in the Sum of Lesion Measurements
    End point description
    The number of subjects analysed includes all participants with baseline and one post-baseline evaluable tumor assessment.
    End point type
    Secondary
    End point timeframe
    Day 1 to end of follow-up, up to a maximum of 60 weeks
    End point values
    		 Dose Expansion Part: Bladder Cancer Dose Expansion Part: Cervical Cancer Dose Expansion Part: Endometrial Cancer Dose Expansion Part: Esophageal Cancer Dose Expansion Part: Non-Small Cell Lung Cancer (NSCLC) Dose Expansion Part: Ovarian Cancer Dose Expansion Part: Prostate Cancer
    Number of subjects analysed
    14
    50
    12
    11
    14
    33
    12
    Units: millimeter(s)
        median (full range (min-max))
    6.00 (-127.0 to 41.0)
    -8.50 (-64.0 to 50.0)
    1.00 (-11.0 to 26.0)
    -2.00 (-51.0 to 40.0)
    0.00 (-59.0 to 31.0)
    -4.00 (-41.0 to 115.0)
    -1.00 (-11.0 to 15.0)
    No statistical analyses for this end point

    Secondary: Dose Escalation and Expansion Part: Percentage Change from Baseline in Prostate Specific Antigen (PSA)

    		 Close Top of page
    End point title
    		 Dose Escalation and Expansion Part: Percentage Change from Baseline in Prostate Specific Antigen (PSA)
    End point description
    PSA was only assessed in participants with castrate-resistant prostate cancer. 99999 = no evaluable data. 99999 is presented when no participants had evaluable data or only 1 participant had evaluable data, so geometric coefficient of variation could not be calculated. The 'number of subjects analysed' number includes all participants with baseline and end of study evaluable assessment.
    End point type
    Secondary
    End point timeframe
    Day 1 to end of follow-up, up to a maximum of 60 weeks
    End point values
    		 Dose Escalation Part: 0.3 mg/kg Dose Escalation Part: 0.6 mg/kg Dose Escalation Part: 0.9 mg/kg Dose Escalation Part: 1.2 mg/kg Dose Escalation Part: 1.5 mg/kg Dose Escalation Part: 1.8 mg/kg Dose Escalation Part: 2.0 mg/kg Dose Escalation Part: 2.2 mg/kg Dose Expansion Part: Prostate Cancer
    Number of subjects analysed
    0 [46]
    1
    0 [47]
    1
    1
    0 [48]
    0 [49]
    0 [50]
    11
    Units: percentage change in PSA
        median (full range (min-max))
    ( to )
    64.35 (64.35 to 64.35)
    ( to )
    40.91 (40.91 to 40.91)
    3.92 (3.92 to 3.92)
    ( to )
    ( to )
    ( to )
    60.07 (3.4 to 996.5)
    Notes
    [46] - No participants with castrate-resistant prostate cancer
    [47] - No participants with castrate-resistant prostate cancer
    [48] - No participants with castrate-resistant prostate cancer
    [49] - No participants with castrate-resistant prostate cancer
    [50] - No participants with castrate-resistant prostate cancer
    No statistical analyses for this end point

    Secondary: Dose Escalation and Expansion Part: Percentage Change from Baseline in CA-125

    		 Close Top of page
    End point title
    		 Dose Escalation and Expansion Part: Percentage Change from Baseline in CA-125
    End point description
    In the dose escalation part, CA-125 was only assessed for participants with ovarian cancer. In the dose expansion part, CA-125 was intended to be assessed only for participants with ovarian and endometrium cancer, but was additionally assessed for some participants with NSCLC and cervical cancer. 99999 = no evaluable data. 99999 is presented when no participants had evaluable data or only 1 participant had evaluable data, so geometric coefficient of variation could not be calculated. The 'number of subjects analysed' number includes all participants with baseline and end of study evaluable assessment.
    End point type
    Secondary
    End point timeframe
    Day 1 to end of follow-up, up to a maximum of 60 weeks
    End point values
    		 Dose Escalation Part: 0.3 mg/kg Dose Escalation Part: 0.6 mg/kg Dose Escalation Part: 0.9 mg/kg Dose Escalation Part: 1.2 mg/kg Dose Escalation Part: 1.5 mg/kg Dose Escalation Part: 1.8 mg/kg Dose Escalation Part: 2.0 mg/kg Dose Escalation Part: 2.2 mg/kg Dose Expansion Part: Cervical Cancer Dose Expansion Part: Endometrial Cancer Dose Expansion Part: Non-Small Cell Lung Cancer (NSCLC) Dose Expansion Part: Ovarian Cancer
    Number of subjects analysed
    0 [51]
    0 [52]
    0 [53]
    1
    0 [54]
    1
    1
    2
    8
    10
    3
    25
    Units: percentage change
        median (full range (min-max))
    ( to )
    ( to )
    ( to )
    18.75 (18.75 to 18.75)
    ( to )
    -13.98 (-13.98 to -13.98)
    113.71 (113.71 to 113.71)
    11.62 (-22.7 to 45.9)
    -25.17 (-88.7 to 240.5)
    37.85 (-46.1 to 666.2)
    180.94 (47.1 to 980.5)
    73.19 (-89.0 to 1924.4)
    Notes
    [51] - No participants with ovarian cancer
    [52] - No participants with ovarian cancer
    [53] - No participants with ovarian cancer
    [54] - No participants with ovarian cancer
    No statistical analyses for this end point

    Secondary: Dose Escalation and Expansion Parts: Objective Response Rate

    		 Close Top of page
    End point title
    		 Dose Escalation and Expansion Parts: Objective Response Rate
    End point description
    Percentage of participants with either a best overall response of complete response (CR) or partial response (PR) as assessed by the investigator per RECIST v1.1. The best overall response is the best response recorded from the start of the treatment until disease progression.
    End point type
    Secondary
    End point timeframe
    Day 1 to end of follow-up, up to a maximum of 60 weeks
    End point values
    		 Dose Escalation Part: 0.3 mg/kg Dose Escalation Part: 0.6 mg/kg Dose Escalation Part: 0.9 mg/kg Dose Escalation Part: 1.2 mg/kg Dose Escalation Part: 1.5 mg/kg Dose Escalation Part: 1.8 mg/kg Dose Escalation Part: 2.0 mg/kg Dose Escalation Part: 2.2 mg/kg Dose Expansion Part: Bladder Cancer Dose Expansion Part: Cervical Cancer Dose Expansion Part: Endometrial Cancer Dose Expansion Part: Esophageal Cancer Dose Expansion Part: Non-Small Cell Lung Cancer (NSCLC) Dose Expansion Part: Ovarian Cancer Dose Expansion Part: Prostate Cancer
    Number of subjects analysed
    3
    3
    3
    3
    3
    3
    3
    6
    15
    55
    14
    15
    15
    36
    18
    Units: Percentage of participants
        number (confidence interval 95%)
    0 (0 to 71)
    0 (0 to 71)
    0 (0 to 71)
    33 (1 to 91)
    0 (0 to 71)
    0 (0 to 71)
    0 (0 to 71)
    0 (0 to 71)
    27 (8 to 55)
    24 (13 to 37)
    7 (0 to 34)
    13 (2 to 40)
    13 (2 to 40)
    14 (5 to 29)
    0 (0 to 19)
    No statistical analyses for this end point

    Secondary: Dose Escalation and Expansion Parts: Disease Control Rate

    		 Close Top of page
    End point title
    		 Dose Escalation and Expansion Parts: Disease Control Rate
    End point description
    Disease control rate was defined as the percentage of participants with CR, PR or SD as per investigator assessment per RECIST version 1.1 after 6, 12, 24 and 36 weeks.
    End point type
    Secondary
    End point timeframe
    At 6, 12, 24 and 36 weeks
    End point values
    		 Dose Escalation Part: 0.3 mg/kg Dose Escalation Part: 0.6 mg/kg Dose Escalation Part: 0.9 mg/kg Dose Escalation Part: 1.2 mg/kg Dose Escalation Part: 1.5 mg/kg Dose Escalation Part: 1.8 mg/kg Dose Escalation Part: 2.0 mg/kg Dose Escalation Part: 2.2 mg/kg Dose Expansion Part: Bladder Cancer Dose Expansion Part: Cervical Cancer Dose Expansion Part: Endometrial Cancer Dose Expansion Part: Esophageal Cancer Dose Expansion Part: Non-Small Cell Lung Cancer (NSCLC) Dose Expansion Part: Ovarian Cancer Dose Expansion Part: Prostate Cancer
    Number of subjects analysed
    3
    3
    3
    3
    3
    3
    3
    6
    15
    55
    14
    15
    15
    36
    18
    Units: Percentage of participants
    number (confidence interval 95%)
        Week 6
    0 (0 to 71)
    33 (1 to 91)
    33 (1 to 91)
    67 (9 to 99)
    33 (1 to 91)
    100 (29 to 100)
    67 (9 to 99)
    50 (12 to 88)
    47 (21 to 73)
    60 (46 to 73)
    64 (35 to 87)
    40 (16 to 68)
    60 (32 to 84)
    72 (55 to 86)
    61 (36 to 83)
        Week 12
    0 (0 to 71)
    33 (1 to 91)
    33 (1 to 91)
    67 (9 to 99)
    0 (0 to 71)
    67 (9 to 99)
    33 (1 to 91)
    0 (0 to 46)
    33 (12 to 62)
    47 (34 to 61)
    43 (18 to 71)
    20 (4 to 48)
    13 (2 to 40)
    42 (26 to 59)
    28 (10 to 53)
        Week 24
    0 (0 to 71)
    33 (1 to 91)
    0 (0 to 71)
    33 (1 to 91)
    0 (0 to 71)
    0 (0 to 71)
    0 (0 to 71)
    0 (0 to 46)
    20 (4 to 48)
    18 (9 to 31)
    21 (5 to 51)
    7 (0 to 32)
    13 (2 to 40)
    14 (5 to 29)
    6 (0 to 27)
        Week 36
    0 (0 to 71)
    33 (1 to 91)
    0 (0 to 71)
    33 (1 to 91)
    0 (0 to 71)
    0 (0 to 71)
    0 (0 to 71)
    0 (0 to 46)
    7 (0 to 32)
    11 (4 to 22)
    0 (0 to 23)
    0 (0 to 22)
    7 (0 to 32)
    3 (0 to 15)
    6 (0 to 27)
    No statistical analyses for this end point

    Secondary: Dose Escalation and Expansion Parts: Progression Free Survival (PFS)

    		 Close Top of page
    End point title
    		 Dose Escalation and Expansion Parts: Progression Free Survival (PFS)
    End point description
    PFS was defined as the median time in weeks from Day 1 in Cycle 1 to first disease progression or death as assessed by the investigator. Only deaths that occurred within 60 days of the last visit were considered in the analysis and result are presented based on Kaplan-Meier estimates. Any results that could not be estimated are indicated as 99999.
    End point type
    Secondary
    End point timeframe
    Day 1 to end of follow-up, up to a maximum of 60 weeks
    End point values
    		 Dose Escalation Part: 0.3 mg/kg Dose Escalation Part: 0.6 mg/kg Dose Escalation Part: 0.9 mg/kg Dose Escalation Part: 1.2 mg/kg Dose Escalation Part: 1.5 mg/kg Dose Escalation Part: 1.8 mg/kg Dose Escalation Part: 2.0 mg/kg Dose Escalation Part: 2.2 mg/kg Dose Expansion Part: Bladder Cancer Dose Expansion Part: Cervical Cancer Dose Expansion Part: Endometrial Cancer Dose Expansion Part: Esophageal Cancer Dose Expansion Part: Non-Small Cell Lung Cancer (NSCLC) Dose Expansion Part: Ovarian Cancer Dose Expansion Part: Prostate Cancer
    Number of subjects analysed
    3
    3
    3
    3
    3
    3
    3
    6
    15
    55
    14
    15
    15
    36
    18
    Units: weeks
        median (confidence interval 95%)
    5.1 (4.9 to 5.4)
    6.0 (3.9 to 49.1)
    6.1 (4.9 to 99999)
    27.1 (6.0 to 99999)
    6.1 (5.3 to 10.4)
    17.1 (11.3 to 99999)
    12.3 (5.0 to 14.1)
    11.3 (2.1 to 11.3)
    11.0 (5.1 to 43.0)
    18.1 (9.3 to 23.0)
    99999 (5.1 to 99999)
    10.1 (5.3 to 17.0)
    13.0 (5.1 to 17.3)
    13.0 (12.1 to 18.3)
    12.9 (7.1 to 23.7)
    No statistical analyses for this end point

    Secondary: Dose Expansion Parts: Duration of Response (DOR)

    		 Close Top of page
    End point title
    		 Dose Expansion Parts: Duration of Response (DOR)
    End point description
    DOR was defined as the median time in weeks from when confirmed response was first documented until the first documented disease progression, or death from any cause, whichever was earliest as assessed by the investigator. A responder was defined as any participant with a best overall response of confirmed CR or PR. The 'subjects analysed' number only includes participants considered a responder. Any results in the dose expansion part of the study that could not be estimated are indicated as 99999. The duration of response could not be estimated for the dose escalation part of the study as all participants who responded did not have disease progression or died due to any cause.
    End point type
    Secondary
    End point timeframe
    Day 1 to end of follow-up, up to a maximum of 60 weeks
    End point values
    		 Dose Expansion Part: Bladder Cancer Dose Expansion Part: Cervical Cancer Dose Expansion Part: Endometrial Cancer Dose Expansion Part: Esophageal Cancer Dose Expansion Part: Non-Small Cell Lung Cancer (NSCLC) Dose Expansion Part: Ovarian Cancer Dose Expansion Part: Prostate Cancer
    Number of subjects analysed
    4
    13
    1
    2
    2
    5
    0 [55]
    Units: weeks
        median (confidence interval 95%)
    32.0 (11.0 to 32.0)
    18.4 (13.1 to 41.7)
    99999 (99999 to 99999)
    18.3 (11.6 to 25.0)
    99999 (12.0 to 99999)
    21.4 (13.1 to 29.6)
    ( to )
    Notes
    [55] - No participants with confirmed CR or PR.
    No statistical analyses for this end point

    Adverse events

    		 Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    Treatment emergent adverse events are reported from Day 1 to 30 days after dosing. The exposure ranged from 1 to 249 days in the escalation part and from 1 to 325 days in the expansion part.
    Adverse event reporting additional description
    Deaths from all causes are reported from day of enrollment to end of follow up (up to maximum of 60 weeks).
    Assessment type
    		 Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    		 MedDRA
    Dictionary version
    22.0
    Reporting groups
    Reporting group title
    Dose Escalation Part: 0.3 mg/kg
    Reporting group description
    		 -

    Reporting group title
    Dose Escalation Part: 0.6 mg/kg
    Reporting group description
    		 -

    Reporting group title
    Dose Escalation Part: 0.9 mg/kg
    Reporting group description
    		 -

    Reporting group title
    Dose Escalation Part: 1.2 mg/kg
    Reporting group description
    		 -

    Reporting group title
    Dose Escalation Part: 1.5 mg/kg
    Reporting group description
    		 -

    Reporting group title
    Dose Escalation Part: 1.8 mg/kg
    Reporting group description
    		 -

    Reporting group title
    Dose Escalation Part: 2.0 mg/kg
    Reporting group description
    		 -

    Reporting group title
    Dose Escalation Part: 2.2 mg/kg
    Reporting group description
    		 -

    Reporting group title
    Dose Expansion Part: Bladder Cancer
    Reporting group description
    		 -

    Reporting group title
    Dose Expansion Part: Cervical Cancer
    Reporting group description
    		 -

    Reporting group title
    Dose Expansion Part: Endometrial Cancer
    Reporting group description
    		 -

    Reporting group title
    Dose Expansion Part: Esophageal Cancer
    Reporting group description
    		 -

    Reporting group title
    Dose Expansion Part: Non-Small-Cell Lung Cancer
    Reporting group description
    		 -

    Reporting group title
    Dose Expansion Part: Ovarian Cancer
    Reporting group description
    		 -

    Reporting group title
    Dose Expansion Part: Prostate Cancer
    Reporting group description
    		 -

    Serious adverse events
    		 Dose Escalation Part: 0.3 mg/kg Dose Escalation Part: 0.6 mg/kg Dose Escalation Part: 0.9 mg/kg Dose Escalation Part: 1.2 mg/kg Dose Escalation Part: 1.5 mg/kg Dose Escalation Part: 1.8 mg/kg Dose Escalation Part: 2.0 mg/kg Dose Escalation Part: 2.2 mg/kg Dose Expansion Part: Bladder Cancer Dose Expansion Part: Cervical Cancer Dose Expansion Part: Endometrial Cancer Dose Expansion Part: Esophageal Cancer Dose Expansion Part: Non-Small-Cell Lung Cancer Dose Expansion Part: Ovarian Cancer Dose Expansion Part: Prostate Cancer
    Total subjects affected by serious adverse events
         subjects affected / exposed
    2 / 3 (66.67%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    2 / 3 (66.67%)
    2 / 3 (66.67%)
    2 / 3 (66.67%)
    2 / 3 (66.67%)
    4 / 6 (66.67%)
    7 / 15 (46.67%)
    26 / 55 (47.27%)
    5 / 14 (35.71%)
    8 / 15 (53.33%)
    6 / 15 (40.00%)
    13 / 36 (36.11%)
    6 / 18 (33.33%)
         number of deaths (all causes)
    2
    1
    0
    0
    0
    0
    0
    0
    0
    2
    0
    1
    1
    2
    1
         number of deaths resulting from adverse events
    2
    1
    0
    0
    0
    0
    0
    0
    0
    2
    0
    1
    0
    1
    0
    Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    Malignant neoplasm progression
         subjects affected / exposed
    2 / 3 (66.67%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    2 / 55 (3.64%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Oesophageal cancer metastatic
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    1 / 15 (6.67%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    Tumour pain
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    1 / 55 (1.82%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Vascular disorders
    Vascular disorders
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    1 / 15 (6.67%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    General disorders and administration site conditions
    Malaise
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    1 / 55 (1.82%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    2 / 36 (5.56%)
    0 / 18 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    3 / 3
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pyrexia
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    2 / 55 (3.64%)
    0 / 14 (0.00%)
    1 / 15 (6.67%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 2
    0 / 0
    2 / 2
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    General physical health deterioration
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    1 / 15 (6.67%)
    0 / 15 (0.00%)
    1 / 36 (2.78%)
    0 / 18 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    Catheter site pain
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    1 / 55 (1.82%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Mucosal inflammation
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 6 (16.67%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    1 / 18 (5.56%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Fatigue
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 6 (16.67%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Immune system disorders
    Hypersensitivity
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    1 / 15 (6.67%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Reproductive system and breast disorders
    Vaginal haemorrhage
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    2 / 55 (3.64%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    3 / 3
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Female genital tract fistula
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    1 / 55 (1.82%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Respiratory, thoracic and mediastinal disorders
    Dyspnoea
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    1 / 55 (1.82%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Epistaxis
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    1 / 15 (6.67%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hypoxia
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    1 / 55 (1.82%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pulmonary embolism
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    1 / 15 (6.67%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pharyngeal haemorrhage
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Psychiatric disorders
    Anxiety
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    1 / 55 (1.82%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Insomnia
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    1 / 15 (6.67%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Product issues
    Stent malfunction
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    1 / 55 (1.82%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Investigations
    Blood creatinine increased
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    1 / 15 (6.67%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Transaminases increased
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    1 / 36 (2.78%)
    0 / 18 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Injury, poisoning and procedural complications
    Stress fracture
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    1 / 55 (1.82%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cardiac disorders
    Supraventricular extrasystoles
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    1 / 55 (1.82%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Nervous system disorders
    Peripheral sensorimotor neuropathy
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    1 / 15 (6.67%)
    1 / 55 (1.82%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cerebrovascular accident
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    1 / 36 (2.78%)
    0 / 18 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Guillain-barre syndrome
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    1 / 36 (2.78%)
    0 / 18 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Headache
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    1 / 55 (1.82%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Ischaemic stroke
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    1 / 36 (2.78%)
    0 / 18 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Lethargy
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    1 / 55 (1.82%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Neuropathy peripheral
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    1 / 15 (6.67%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Blood and lymphatic system disorders
    Anaemia
         subjects affected / exposed
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    2 / 55 (3.64%)
    0 / 14 (0.00%)
    1 / 15 (6.67%)
    0 / 15 (0.00%)
    1 / 36 (2.78%)
    0 / 18 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    2 / 2
    0 / 0
    1 / 1
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Febrile neutropenia
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    1 / 15 (6.67%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    1 / 15 (6.67%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Neutropenia
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    1 / 36 (2.78%)
    0 / 18 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Ear and labyrinth disorders
    Hypoacusis
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    1 / 14 (7.14%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Gastrointestinal disorders
    Vomiting
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    4 / 55 (7.27%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    2 / 36 (5.56%)
    0 / 18 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    3 / 4
    0 / 0
    0 / 0
    0 / 0
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Abdominal pain
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    2 / 6 (33.33%)
    0 / 15 (0.00%)
    2 / 55 (3.64%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    2 / 36 (5.56%)
    1 / 18 (5.56%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 1
    0 / 0
    0 / 0
    0 / 2
    0 / 0
    2 / 2
    0 / 0
    0 / 0
    0 / 0
    2 / 2
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Constipation
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    2 / 55 (3.64%)
    0 / 14 (0.00%)
    1 / 15 (6.67%)
    0 / 15 (0.00%)
    1 / 36 (2.78%)
    0 / 18 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 2
    0 / 0
    0 / 1
    0 / 0
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Diarrhoea
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    1 / 55 (1.82%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    2 / 36 (5.56%)
    0 / 18 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    1 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Dysphagia
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    1 / 55 (1.82%)
    0 / 14 (0.00%)
    2 / 15 (13.33%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 2
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Colitis
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    1 / 15 (6.67%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    1 / 15 (6.67%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Nausea
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    2 / 55 (3.64%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    2 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Gastrointestinal haemorrhage
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    1 / 14 (7.14%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Gastrointestinal ulcer haemorrhage
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    1 / 15 (6.67%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Large intestinal obstruction
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    1 / 55 (1.82%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Oesophageal perforation
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    1 / 15 (6.67%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Small intestinal obstruction
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    1 / 36 (2.78%)
    0 / 18 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Subileus
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    1 / 36 (2.78%)
    0 / 18 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Intestinal obstruction
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Ascites
         subjects affected / exposed
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Gastritis
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hepatobiliary disorders
    Hyperbilirubinaemia
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    1 / 18 (5.56%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Skin and subcutaneous tissue disorders
    Rash
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    1 / 18 (5.56%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Renal and urinary disorders
    Haematuria
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    1 / 55 (1.82%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    2 / 18 (11.11%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Urinary tract obstruction
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    1 / 55 (1.82%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Acute kidney injury
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 6 (16.67%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Musculoskeletal and connective tissue disorders
    Back pain
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    1 / 55 (1.82%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Muscular weakness
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    1 / 15 (6.67%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Musculoskeletal pain
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    1 / 14 (7.14%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pain in extremity
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    1 / 18 (5.56%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Myalgia
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Infections and infestations
    Urinary tract infection
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    2 / 55 (3.64%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    2 / 36 (5.56%)
    0 / 18 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 3
    0 / 0
    0 / 0
    0 / 0
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Infection
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    1 / 55 (1.82%)
    0 / 14 (0.00%)
    1 / 15 (6.67%)
    0 / 15 (0.00%)
    1 / 36 (2.78%)
    0 / 18 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 1
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Conjunctivitis
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    1 / 14 (7.14%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    1 / 36 (2.78%)
    0 / 18 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Lower respiratory tract infection
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    1 / 14 (7.14%)
    1 / 15 (6.67%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    1 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Sepsis
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    1 / 36 (2.78%)
    1 / 18 (5.56%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Upper respiratory tract infection
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    1 / 15 (6.67%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 2
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Bacterial sepsis
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    1 / 55 (1.82%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cellulitis
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    1 / 36 (2.78%)
    0 / 18 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Clostridium difficile colitis
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    1 / 36 (2.78%)
    0 / 18 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Device related infection
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    1 / 55 (1.82%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Kidney infection
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    1 / 36 (2.78%)
    0 / 18 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Micrococcus infection
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    1 / 55 (1.82%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Neutropenic sepsis
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    1 / 18 (5.56%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pneumonia
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    1 / 15 (6.67%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Respiratory tract infection
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    1 / 15 (6.67%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Staphylococcal infection
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    1 / 55 (1.82%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Urosepsis
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    1 / 55 (1.82%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cystitis escherichia
         subjects affected / exposed
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Klebsiella infection
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Metabolism and nutrition disorders
    Hyponatraemia
         subjects affected / exposed
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    1 / 15 (6.67%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    1 / 15 (6.67%)
    0 / 36 (0.00%)
    1 / 18 (5.56%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hypokalaemia
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    1 / 55 (1.82%)
    1 / 14 (7.14%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Diabetes mellitus inadequate control
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    1 / 15 (6.67%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hyperglycaemia
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    1 / 15 (6.67%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hypoglycaemia
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    1 / 18 (5.56%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Diabetes mellitus
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 6 (16.67%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 5%
    Non-serious adverse events
    		 Dose Escalation Part: 0.3 mg/kg Dose Escalation Part: 0.6 mg/kg Dose Escalation Part: 0.9 mg/kg Dose Escalation Part: 1.2 mg/kg Dose Escalation Part: 1.5 mg/kg Dose Escalation Part: 1.8 mg/kg Dose Escalation Part: 2.0 mg/kg Dose Escalation Part: 2.2 mg/kg Dose Expansion Part: Bladder Cancer Dose Expansion Part: Cervical Cancer Dose Expansion Part: Endometrial Cancer Dose Expansion Part: Esophageal Cancer Dose Expansion Part: Non-Small-Cell Lung Cancer Dose Expansion Part: Ovarian Cancer Dose Expansion Part: Prostate Cancer
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    3 / 3 (100.00%)
    3 / 3 (100.00%)
    3 / 3 (100.00%)
    3 / 3 (100.00%)
    3 / 3 (100.00%)
    3 / 3 (100.00%)
    3 / 3 (100.00%)
    6 / 6 (100.00%)
    15 / 15 (100.00%)
    55 / 55 (100.00%)
    14 / 14 (100.00%)
    15 / 15 (100.00%)
    15 / 15 (100.00%)
    36 / 36 (100.00%)
    18 / 18 (100.00%)
    Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    Tumour pain
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    1 / 15 (6.67%)
    0 / 55 (0.00%)
    1 / 14 (7.14%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    1
    0
    0
    0
    0
    Cancer pain
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    1 / 14 (7.14%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    2
    0
    0
    0
    0
    Melanocytic naevus
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    Vascular disorders
    Flushing
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    1 / 15 (6.67%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    5 / 36 (13.89%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    0
    0
    1
    0
    0
    0
    0
    6
    0
    Hypotension
         subjects affected / exposed
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    4 / 55 (7.27%)
    1 / 14 (7.14%)
    1 / 15 (6.67%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    1
    0
    0
    1
    0
    0
    1
    0
    0
    4
    1
    1
    0
    0
    0
    Hypertension
         subjects affected / exposed
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    2 / 15 (13.33%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    1 / 15 (6.67%)
    1 / 15 (6.67%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    2
    0
    0
    0
    0
    0
    0
    0
    3
    0
    0
    1
    1
    0
    0
    Hot flush
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    1 / 15 (6.67%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    Intermittent claudication
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    1 / 14 (7.14%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    Lymphoedema
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    1 / 15 (6.67%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    Orthostatic hypotension
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    Phlebitis
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    0
    0
    General disorders and administration site conditions
    Fatigue
         subjects affected / exposed
    3 / 3 (100.00%)
    1 / 3 (33.33%)
    1 / 3 (33.33%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    3 / 3 (100.00%)
    0 / 3 (0.00%)
    4 / 6 (66.67%)
    8 / 15 (53.33%)
    29 / 55 (52.73%)
    10 / 14 (71.43%)
    10 / 15 (66.67%)
    8 / 15 (53.33%)
    15 / 36 (41.67%)
    15 / 18 (83.33%)
         occurrences all number
    3
    3
    1
    1
    0
    3
    0
    4
    10
    34
    12
    10
    11
    18
    16
    Pyrexia
         subjects affected / exposed
    2 / 3 (66.67%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    4 / 6 (66.67%)
    2 / 15 (13.33%)
    11 / 55 (20.00%)
    1 / 14 (7.14%)
    2 / 15 (13.33%)
    0 / 15 (0.00%)
    4 / 36 (11.11%)
    0 / 18 (0.00%)
         occurrences all number
    4
    0
    2
    1
    0
    0
    0
    4
    2
    13
    1
    3
    0
    5
    0
    Mucosal inflammation
         subjects affected / exposed
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    1 / 6 (16.67%)
    1 / 15 (6.67%)
    5 / 55 (9.09%)
    2 / 14 (14.29%)
    0 / 15 (0.00%)
    2 / 15 (13.33%)
    2 / 36 (5.56%)
    0 / 18 (0.00%)
         occurrences all number
    2
    0
    1
    0
    0
    0
    1
    1
    1
    5
    2
    0
    2
    2
    0
    Oedema peripheral
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    1 / 15 (6.67%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    1 / 15 (6.67%)
    2 / 15 (13.33%)
    5 / 36 (13.89%)
    1 / 18 (5.56%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    0
    0
    1
    0
    0
    1
    2
    5
    1
    Chills
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 6 (16.67%)
    1 / 15 (6.67%)
    3 / 55 (5.45%)
    2 / 14 (14.29%)
    1 / 15 (6.67%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    1
    2
    3
    2
    1
    0
    0
    0
    Malaise
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    1 / 14 (7.14%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    5 / 36 (13.89%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    7
    0
    Asthenia
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    1 / 14 (7.14%)
    1 / 15 (6.67%)
    0 / 15 (0.00%)
    3 / 36 (8.33%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    1
    0
    5
    0
    Chest pain
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    1 / 3 (33.33%)
    0 / 6 (0.00%)
    1 / 15 (6.67%)
    0 / 55 (0.00%)
    1 / 14 (7.14%)
    0 / 15 (0.00%)
    1 / 15 (6.67%)
    0 / 36 (0.00%)
    2 / 18 (11.11%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    1
    0
    1
    0
    1
    0
    1
    0
    2
    Influenza like illness
         subjects affected / exposed
    1 / 3 (33.33%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    3 / 55 (5.45%)
    2 / 14 (14.29%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    1
    1
    0
    0
    0
    0
    0
    0
    0
    3
    2
    0
    0
    0
    0
    Pain
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    1 / 15 (6.67%)
    2 / 36 (5.56%)
    1 / 18 (5.56%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    2
    1
    Peripheral swelling
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    1 / 15 (6.67%)
    0 / 15 (0.00%)
    2 / 36 (5.56%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    1
    0
    0
    0
    0
    0
    1
    0
    2
    0
    Chest discomfort
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    1 / 15 (6.67%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    Face oedema
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    1 / 14 (7.14%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    Gait disturbance
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    1 / 14 (7.14%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    1
    0
    0
    0
    0
    Infusion site reaction
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    1 / 15 (6.67%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    Swelling
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    1 / 15 (6.67%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    Oedema
         subjects affected / exposed
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    Immune system disorders
    Hypersensitivity
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    2 / 15 (13.33%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    2
    0
    0
    Contrast media allergy
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    1 / 15 (6.67%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    Seasonal allergy
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    1 / 18 (5.56%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    Reproductive system and breast disorders
    Vaginal haemorrhage
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    6 / 55 (10.91%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    3 / 36 (8.33%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    1
    0
    0
    0
    7
    0
    0
    0
    3
    0
    Balanoposthitis
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    1 / 15 (6.67%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    Metrorrhagia
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    1 / 14 (7.14%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    Testicular pain
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    1 / 18 (5.56%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    Vulvovaginal dryness
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    0
    0
    0
    Respiratory, thoracic and mediastinal disorders
    Epistaxis
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    3 / 3 (100.00%)
    2 / 3 (66.67%)
    3 / 3 (100.00%)
    2 / 3 (66.67%)
    4 / 6 (66.67%)
    13 / 15 (86.67%)
    28 / 55 (50.91%)
    11 / 14 (78.57%)
    8 / 15 (53.33%)
    11 / 15 (73.33%)
    30 / 36 (83.33%)
    12 / 18 (66.67%)
         occurrences all number
    0
    0
    0
    4
    3
    4
    2
    5
    13
    40
    13
    10
    15
    34
    12
    Dyspnoea
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 6 (0.00%)
    3 / 15 (20.00%)
    8 / 55 (14.55%)
    3 / 14 (21.43%)
    2 / 15 (13.33%)
    3 / 15 (20.00%)
    6 / 36 (16.67%)
    2 / 18 (11.11%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    1
    0
    3
    8
    3
    2
    3
    7
    2
    Cough
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 6 (0.00%)
    1 / 15 (6.67%)
    5 / 55 (9.09%)
    1 / 14 (7.14%)
    3 / 15 (20.00%)
    5 / 15 (33.33%)
    3 / 36 (8.33%)
    1 / 18 (5.56%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    1
    0
    1
    8
    1
    3
    5
    3
    1
    Nasal congestion
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    2 / 3 (66.67%)
    1 / 3 (33.33%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    5 / 55 (9.09%)
    1 / 14 (7.14%)
    0 / 15 (0.00%)
    1 / 15 (6.67%)
    4 / 36 (11.11%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    2
    1
    1
    0
    0
    0
    5
    1
    0
    1
    6
    0
    Dysphonia
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    1 / 15 (6.67%)
    3 / 55 (5.45%)
    1 / 14 (7.14%)
    3 / 15 (20.00%)
    1 / 15 (6.67%)
    0 / 36 (0.00%)
    1 / 18 (5.56%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    0
    0
    1
    3
    1
    3
    1
    0
    1
    Rhinorrhoea
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 6 (16.67%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    2 / 14 (14.29%)
    0 / 15 (0.00%)
    2 / 15 (13.33%)
    6 / 36 (16.67%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    2
    0
    2
    6
    0
    Oropharyngeal pain
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 6 (16.67%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    2 / 15 (13.33%)
    3 / 36 (8.33%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    5
    3
    0
    Haemoptysis
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    3 / 15 (20.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    1 / 15 (6.67%)
    1 / 15 (6.67%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    3
    0
    0
    1
    1
    0
    0
    Nasal inflammation
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    1 / 14 (7.14%)
    1 / 15 (6.67%)
    1 / 15 (6.67%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    1
    1
    0
    0
    Nasal obstruction
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    3 / 36 (8.33%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    3
    0
    Productive cough
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    1 / 15 (6.67%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    3
    0
    0
    Catarrh
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    1 / 15 (6.67%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    Dry throat
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    1 / 15 (6.67%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    Dyspnoea exertional
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    1 / 14 (7.14%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    Hiccups
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    1 / 18 (5.56%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    Laryngeal inflammation
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    1 / 15 (6.67%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    Nasal crusting
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    1 / 15 (6.67%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    Pulmonary embolism
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    1 / 15 (6.67%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    Pulmonary haemorrhage
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    1 / 15 (6.67%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    Rales
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    1 / 14 (7.14%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    Sinus pain
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    1 / 15 (6.67%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    Sneezing
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    1 / 15 (6.67%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    Pleural effusion
         subjects affected / exposed
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    1
    0
    0
    1
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    Paranasal sinus hypersecretion
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    0
    0
    Pneumonia aspiration
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    Pneumonitis
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 6 (16.67%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    0
    Psychiatric disorders
    Insomnia
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 6 (0.00%)
    2 / 15 (13.33%)
    6 / 55 (10.91%)
    2 / 14 (14.29%)
    1 / 15 (6.67%)
    4 / 15 (26.67%)
    6 / 36 (16.67%)
    2 / 18 (11.11%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    1
    0
    2
    6
    2
    1
    4
    7
    2
    Depressed mood
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    1 / 14 (7.14%)
    0 / 15 (0.00%)
    3 / 15 (20.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    3
    0
    0
    Depression
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    2 / 36 (5.56%)
    1 / 18 (5.56%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    2
    1
    Anxiety
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    1 / 15 (6.67%)
    1 / 15 (6.67%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    1
    1
    0
    0
    Confusional state
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    1 / 15 (6.67%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    Mood altered
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    1 / 15 (6.67%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    Panic attack
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    1 / 14 (7.14%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    Restlessness
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    1 / 15 (6.67%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    Sleep disorder
         subjects affected / exposed
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 6 (16.67%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    1 / 15 (6.67%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    1
    0
    0
    Investigations
    Weight decreased
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    2 / 3 (66.67%)
    0 / 3 (0.00%)
    1 / 6 (16.67%)
    4 / 15 (26.67%)
    9 / 55 (16.36%)
    4 / 14 (28.57%)
    2 / 15 (13.33%)
    2 / 15 (13.33%)
    3 / 36 (8.33%)
    6 / 18 (33.33%)
         occurrences all number
    0
    0
    0
    0
    0
    2
    0
    1
    4
    10
    4
    2
    2
    3
    6
    Aspartate aminotransferase increased
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    2 / 6 (33.33%)
    1 / 15 (6.67%)
    6 / 55 (10.91%)
    3 / 14 (21.43%)
    3 / 15 (20.00%)
    2 / 15 (13.33%)
    2 / 36 (5.56%)
    2 / 18 (11.11%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    0
    2
    1
    9
    5
    3
    2
    2
    2
    Alanine aminotransferase increased
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    2 / 6 (33.33%)
    0 / 15 (0.00%)
    7 / 55 (12.73%)
    3 / 14 (21.43%)
    3 / 15 (20.00%)
    1 / 15 (6.67%)
    0 / 36 (0.00%)
    2 / 18 (11.11%)
         occurrences all number
    0
    0
    1
    0
    0
    1
    0
    2
    0
    8
    3
    3
    1
    0
    2
    Blood alkaline phosphatase increased
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 6 (16.67%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    1 / 14 (7.14%)
    3 / 15 (20.00%)
    2 / 15 (13.33%)
    0 / 36 (0.00%)
    1 / 18 (5.56%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    2
    3
    2
    0
    2
    Blood creatinine increased
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    4 / 55 (7.27%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    1 / 18 (5.56%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    5
    0
    0
    0
    0
    2
    Gamma-glutamyltransferase increased
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    3 / 14 (21.43%)
    1 / 15 (6.67%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    1 / 18 (5.56%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    3
    1
    0
    0
    1
    Vital dye staining cornea present
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    3 / 55 (5.45%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    3
    0
    0
    0
    0
    0
    White blood cell count decreased
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    1 / 6 (16.67%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    1 / 14 (7.14%)
    0 / 15 (0.00%)
    1 / 15 (6.67%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    2
    0
    1
    0
    0
    3
    0
    2
    0
    0
    Blood creatine phosphokinase increased
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    1 / 6 (16.67%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    1 / 15 (6.67%)
    1 / 15 (6.67%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    0
    1
    0
    0
    0
    1
    1
    0
    0
    Haemoglobin decreased
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    2 / 36 (5.56%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    2
    0
    Platelet count decreased
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    1 / 14 (7.14%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    1 / 18 (5.56%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    1
    Lymphocyte count decreased
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    1 / 15 (6.67%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    2
    0
    0
    0
    Neutrophil count decreased
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 6 (16.67%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    1 / 14 (7.14%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    2
    0
    0
    0
    0
    Blood magnesium decreased
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    1 / 15 (6.67%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    Blood potassium increased
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    1 / 18 (5.56%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    Blood urea increased
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    1 / 14 (7.14%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    Blood urine present
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    1 / 15 (6.67%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    Body temperature increased
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    1 / 14 (7.14%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    Conjunctival staining
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    1 / 15 (6.67%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    Transaminases increased
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 6 (16.67%)
    0 / 15 (0.00%)
    1 / 55 (1.82%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    1 / 36 (2.78%)
    0 / 18 (0.00%)
         occurrences all number
    0
    1
    0
    1
    0
    0
    0
    1
    0
    1
    0
    0
    0
    1
    0
    Blood fibrinogen increased
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 6 (16.67%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    0
    Serum ferritin increased
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    1 / 6 (16.67%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    4
    0
    1
    0
    0
    0
    0
    0
    0
    0
    Activated partial thromboplastin time prolonged
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 6 (16.67%)
    0 / 15 (0.00%)
    1 / 55 (1.82%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    1
    0
    1
    0
    0
    0
    0
    0
    Blood lactate dehydrogenase increased
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 6 (16.67%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    0
    Blood urea decreased
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 6 (16.67%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    0
    C-reactive protein increased
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    Fibrin d dimer increased
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    Neutrophil count increased
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 6 (16.67%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    0
    White blood cell count increased
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 6 (16.67%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    0
    Injury, poisoning and procedural complications
    Fall
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    4 / 55 (7.27%)
    0 / 14 (0.00%)
    1 / 15 (6.67%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    2 / 18 (11.11%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    5
    0
    1
    0
    0
    2
    Conjunctival scar
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    1 / 14 (7.14%)
    1 / 15 (6.67%)
    0 / 15 (0.00%)
    2 / 36 (5.56%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    1
    0
    2
    0
    Contusion
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    3 / 55 (5.45%)
    0 / 14 (0.00%)
    1 / 15 (6.67%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    3
    0
    1
    0
    0
    0
    Eyelid contusion
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    1 / 14 (7.14%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    Pharynx radiation injury
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    1 / 15 (6.67%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    Skin laceration
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    1 / 15 (6.67%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    Sunburn
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    1 / 15 (6.67%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    Chemical burns of eye
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    Cardiac disorders
    Atrial fibrillation
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    1 / 15 (6.67%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    Pericardial effusion
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    1 / 15 (6.67%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    Sinus tachycardia
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    1 / 15 (6.67%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    Tachycardia
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    1 / 3 (33.33%)
    2 / 6 (33.33%)
    0 / 15 (0.00%)
    2 / 55 (3.64%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    1
    2
    0
    2
    0
    0
    0
    0
    0
    Bradycardia
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 6 (16.67%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    0
    Nervous system disorders
    Neuropathy peripheral
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    1 / 3 (33.33%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    6 / 15 (40.00%)
    16 / 55 (29.09%)
    5 / 14 (35.71%)
    2 / 15 (13.33%)
    3 / 15 (20.00%)
    10 / 36 (27.78%)
    3 / 18 (16.67%)
         occurrences all number
    0
    2
    1
    1
    0
    0
    0
    0
    7
    19
    5
    2
    3
    12
    3
    Peripheral sensory neuropathy
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    1 / 15 (6.67%)
    5 / 55 (9.09%)
    2 / 14 (14.29%)
    0 / 15 (0.00%)
    1 / 15 (6.67%)
    9 / 36 (25.00%)
    1 / 18 (5.56%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    0
    0
    3
    5
    3
    0
    1
    9
    1
    Headache
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 6 (16.67%)
    0 / 15 (0.00%)
    5 / 55 (9.09%)
    3 / 14 (21.43%)
    1 / 15 (6.67%)
    1 / 15 (6.67%)
    5 / 36 (13.89%)
    3 / 18 (16.67%)
         occurrences all number
    0
    0
    1
    1
    0
    0
    0
    1
    0
    7
    3
    1
    2
    6
    3
    Lethargy
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    1 / 15 (6.67%)
    0 / 55 (0.00%)
    1 / 14 (7.14%)
    1 / 15 (6.67%)
    1 / 15 (6.67%)
    2 / 36 (5.56%)
    1 / 18 (5.56%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    1
    1
    1
    2
    2
    Dizziness
         subjects affected / exposed
    1 / 3 (33.33%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    2 / 15 (13.33%)
    0 / 55 (0.00%)
    1 / 14 (7.14%)
    1 / 15 (6.67%)
    1 / 15 (6.67%)
    0 / 36 (0.00%)
    1 / 18 (5.56%)
         occurrences all number
    1
    3
    0
    1
    0
    0
    0
    0
    2
    0
    2
    1
    1
    0
    1
    Dysgeusia
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    1 / 6 (16.67%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    1 / 14 (7.14%)
    1 / 15 (6.67%)
    1 / 15 (6.67%)
    2 / 36 (5.56%)
    1 / 18 (5.56%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    1
    1
    0
    0
    1
    1
    1
    3
    1
    Peripheral motor neuropathy
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    1 / 14 (7.14%)
    0 / 15 (0.00%)
    1 / 15 (6.67%)
    2 / 36 (5.56%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    1
    2
    0
    Polyneuropathy
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    1 / 14 (7.14%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    3 / 18 (16.67%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    3
    Tremor
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    1 / 14 (7.14%)
    1 / 15 (6.67%)
    1 / 15 (6.67%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    1
    1
    0
    0
    Migraine
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    1 / 15 (6.67%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    1 / 15 (6.67%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    2
    0
    0
    0
    Paraesthesia
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 6 (16.67%)
    1 / 15 (6.67%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    1 / 15 (6.67%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    1
    1
    0
    0
    0
    1
    0
    0
    Taste disorder
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    1 / 15 (6.67%)
    1 / 15 (6.67%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    1
    0
    0
    Balance disorder
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    1 / 15 (6.67%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    2
    0
    0
    0
    0
    0
    0
    Ataxia
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    1 / 15 (6.67%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    Brain oedema
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    1 / 15 (6.67%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    Carpal tunnel syndrome
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    1 / 15 (6.67%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    Central pain syndrome
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    1 / 15 (6.67%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    Dysaesthesia
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    1 / 14 (7.14%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    Mental impairment
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    1 / 14 (7.14%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    Myoclonus
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    1 / 15 (6.67%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    Nerve compression
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    1 / 14 (7.14%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    Sciatica
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    1 / 18 (5.56%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    Spinal cord compression
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    1 / 18 (5.56%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    Amputation stump pain
         subjects affected / exposed
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    Blood and lymphatic system disorders
    Anaemia
         subjects affected / exposed
    0 / 3 (0.00%)
    3 / 3 (100.00%)
    1 / 3 (33.33%)
    2 / 3 (66.67%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    1 / 3 (33.33%)
    3 / 6 (50.00%)
    1 / 15 (6.67%)
    13 / 55 (23.64%)
    2 / 14 (14.29%)
    3 / 15 (20.00%)
    2 / 15 (13.33%)
    0 / 36 (0.00%)
    3 / 18 (16.67%)
         occurrences all number
    0
    3
    2
    2
    0
    1
    1
    3
    1
    17
    2
    4
    2
    0
    6
    Neutropenia
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    3 / 55 (5.45%)
    0 / 14 (0.00%)
    1 / 15 (6.67%)
    1 / 15 (6.67%)
    3 / 36 (8.33%)
    1 / 18 (5.56%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    0
    0
    0
    3
    0
    1
    1
    3
    1
    Lymph node pain
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    1 / 15 (6.67%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    Lymphadenopathy
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    1 / 15 (6.67%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    Neutrophilia
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    1 / 15 (6.67%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    Febrile neutropenia
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 6 (16.67%)
    1 / 15 (6.67%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    1 / 15 (6.67%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    1
    1
    0
    0
    1
    0
    0
    0
    Ear and labyrinth disorders
    Ear congestion
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    1 / 15 (6.67%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    Ear pain
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    1 / 15 (6.67%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    Hypoacusis
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    1 / 18 (5.56%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    Vertigo
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    1 / 15 (6.67%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    Tinnitus
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    0
    0
    Eye disorders
    Dry eye
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    2 / 15 (13.33%)
    14 / 55 (25.45%)
    6 / 14 (42.86%)
    2 / 15 (13.33%)
    6 / 15 (40.00%)
    6 / 36 (16.67%)
    2 / 18 (11.11%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    2
    14
    6
    2
    7
    6
    2
    Lacrimation increased
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    1 / 3 (33.33%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    1 / 14 (7.14%)
    3 / 15 (20.00%)
    2 / 15 (13.33%)
    5 / 36 (13.89%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    1
    0
    0
    0
    1
    3
    3
    5
    0
    Blepharitis
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    4 / 55 (7.27%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    5 / 36 (13.89%)
    1 / 18 (5.56%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    4
    0
    0
    0
    5
    1
    Vision blurred
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    1 / 3 (33.33%)
    0 / 6 (0.00%)
    1 / 15 (6.67%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    1 / 15 (6.67%)
    2 / 15 (13.33%)
    6 / 36 (16.67%)
    0 / 18 (0.00%)
         occurrences all number
    0
    1
    0
    1
    0
    1
    1
    0
    1
    0
    0
    1
    2
    6
    0
    Conjunctival ulcer
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    2 / 15 (13.33%)
    4 / 55 (7.27%)
    0 / 14 (0.00%)
    1 / 15 (6.67%)
    0 / 15 (0.00%)
    2 / 36 (5.56%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    2
    4
    0
    1
    0
    2
    0
    Keratitis
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    3 / 55 (5.45%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    1 / 15 (6.67%)
    2 / 36 (5.56%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    5
    0
    0
    1
    2
    0
    Meibomianitis
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    1 / 14 (7.14%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    5 / 36 (13.89%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    5
    0
    Noninfective conjunctivitis
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    1 / 15 (6.67%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    3 / 36 (8.33%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    3
    0
    Symblepharon
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    1 / 15 (6.67%)
    0 / 15 (0.00%)
    3 / 36 (8.33%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    3
    0
    Eye pain
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    1 / 14 (7.14%)
    0 / 15 (0.00%)
    2 / 15 (13.33%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    3
    0
    0
    Ocular hyperaemia
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    1 / 15 (6.67%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    2 / 15 (13.33%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    2
    0
    0
    0
    2
    0
    0
    Cataract
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    1 / 15 (6.67%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    1 / 15 (6.67%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    1 / 18 (5.56%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    1
    0
    0
    1
    Conjunctival hyperaemia
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    1 / 15 (6.67%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    2 / 36 (5.56%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    2
    0
    Ulcerative keratitis
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    3 / 55 (5.45%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    3
    0
    0
    0
    0
    0
    Conjunctival disorder
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    2 / 36 (5.56%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    3
    0
    Foreign body sensation in eyes
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    1 / 15 (6.67%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    1 / 15 (6.67%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    2
    0
    0
    1
    0
    0
    0
    Conjunctival haemorrhage
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    3 / 6 (50.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    1 / 15 (6.67%)
    1 / 15 (6.67%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    4
    0
    0
    0
    1
    1
    0
    0
    Eye pruritus
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    1 / 15 (6.67%)
    0 / 55 (0.00%)
    1 / 14 (7.14%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    1
    0
    0
    0
    0
    Punctate keratitis
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    2 / 36 (5.56%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    2
    0
    Chorioretinopathy
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    1 / 15 (6.67%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    Entropion
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    1 / 36 (2.78%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    Open angle glaucoma
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    1 / 15 (6.67%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    Periorbital oedema
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    1 / 15 (6.67%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    Retinal vein occlusion
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    1 / 15 (6.67%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    Trichiasis
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    1 / 36 (2.78%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    Eye inflammation
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    0
    0
    Eye irritation
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 6 (16.67%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    1 / 15 (6.67%)
    1 / 15 (6.67%)
    2 / 36 (5.56%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    1
    1
    2
    0
    Gastrointestinal disorders
    Nausea
         subjects affected / exposed
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    1 / 3 (33.33%)
    4 / 6 (66.67%)
    7 / 15 (46.67%)
    25 / 55 (45.45%)
    7 / 14 (50.00%)
    7 / 15 (46.67%)
    10 / 15 (66.67%)
    20 / 36 (55.56%)
    12 / 18 (66.67%)
         occurrences all number
    1
    0
    3
    3
    0
    1
    1
    4
    7
    30
    8
    8
    16
    30
    14
    Constipation
         subjects affected / exposed
    2 / 3 (66.67%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    2 / 3 (66.67%)
    1 / 3 (33.33%)
    3 / 6 (50.00%)
    6 / 15 (40.00%)
    19 / 55 (34.55%)
    3 / 14 (21.43%)
    6 / 15 (40.00%)
    5 / 15 (33.33%)
    11 / 36 (30.56%)
    9 / 18 (50.00%)
         occurrences all number
    2
    0
    0
    0
    1
    3
    2
    3
    7
    21
    3
    8
    5
    13
    11
    Diarrhoea
         subjects affected / exposed
    2 / 3 (66.67%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    2 / 3 (66.67%)
    0 / 6 (0.00%)
    3 / 15 (20.00%)
    17 / 55 (30.91%)
    6 / 14 (42.86%)
    2 / 15 (13.33%)
    4 / 15 (26.67%)
    14 / 36 (38.89%)
    5 / 18 (27.78%)
         occurrences all number
    2
    1
    0
    1
    0
    0
    3
    0
    3
    26
    8
    4
    4
    19
    7
    Vomiting
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    2 / 6 (33.33%)
    1 / 15 (6.67%)
    18 / 55 (32.73%)
    4 / 14 (28.57%)
    4 / 15 (26.67%)
    6 / 15 (40.00%)
    11 / 36 (30.56%)
    6 / 18 (33.33%)
         occurrences all number
    0
    0
    3
    0
    0
    1
    0
    2
    1
    23
    6
    5
    6
    18
    9
    Abdominal pain
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 6 (16.67%)
    2 / 15 (13.33%)
    15 / 55 (27.27%)
    1 / 14 (7.14%)
    1 / 15 (6.67%)
    2 / 15 (13.33%)
    8 / 36 (22.22%)
    6 / 18 (33.33%)
         occurrences all number
    0
    0
    0
    3
    0
    0
    0
    1
    2
    17
    1
    1
    2
    9
    8
    Dyspepsia
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    1 / 3 (33.33%)
    0 / 6 (0.00%)
    1 / 15 (6.67%)
    0 / 55 (0.00%)
    2 / 14 (14.29%)
    2 / 15 (13.33%)
    2 / 15 (13.33%)
    4 / 36 (11.11%)
    1 / 18 (5.56%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    1
    0
    1
    0
    2
    2
    2
    4
    1
    Dry mouth
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    3 / 55 (5.45%)
    5 / 14 (35.71%)
    0 / 15 (0.00%)
    2 / 15 (13.33%)
    0 / 36 (0.00%)
    1 / 18 (5.56%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    1
    0
    0
    4
    6
    0
    2
    0
    2
    Stomatitis
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    2 / 3 (66.67%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 6 (0.00%)
    1 / 15 (6.67%)
    0 / 55 (0.00%)
    1 / 14 (7.14%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    6 / 36 (16.67%)
    2 / 18 (11.11%)
         occurrences all number
    0
    0
    4
    0
    0
    0
    1
    0
    1
    0
    1
    0
    0
    7
    2
    Abdominal discomfort
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    3 / 55 (5.45%)
    1 / 14 (7.14%)
    1 / 15 (6.67%)
    0 / 15 (0.00%)
    2 / 36 (5.56%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    4
    2
    1
    0
    2
    0
    Rectal haemorrhage
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    3 / 55 (5.45%)
    0 / 14 (0.00%)
    1 / 15 (6.67%)
    0 / 15 (0.00%)
    2 / 36 (5.56%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    5
    0
    1
    0
    2
    0
    Abdominal pain lower
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    1 / 15 (6.67%)
    0 / 15 (0.00%)
    3 / 36 (8.33%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    3
    0
    Colitis
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    2 / 15 (13.33%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    2 / 15 (13.33%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    2
    0
    0
    2
    0
    0
    0
    Dysphagia
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    4 / 15 (26.67%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    4
    0
    0
    0
    Abdominal distension
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    2 / 36 (5.56%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    2
    0
    Gingival bleeding
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    2 / 14 (14.29%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    2
    0
    0
    0
    0
    Ascites
         subjects affected / exposed
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    1 / 14 (7.14%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    4
    0
    0
    1
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    Cheilitis
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    1 / 15 (6.67%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    Flatulence
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    1 / 15 (6.67%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    Gastritis
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    1 / 15 (6.67%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    0
    0
    1
    0
    0
    0
    0
    0
    0
    Gastrooesophageal reflux disease
         subjects affected / exposed
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    1 / 15 (6.67%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    1
    0
    0
    Haematemesis
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    1 / 14 (7.14%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    Haematochezia
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    1 / 14 (7.14%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    Haemorrhoids
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    1 / 3 (33.33%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    1 / 18 (5.56%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    1
    0
    0
    0
    0
    0
    0
    0
    1
    Melaena
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    1 / 15 (6.67%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    Mouth ulceration
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    1 / 15 (6.67%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    Oesophageal mucosal hyperplasia
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    1 / 15 (6.67%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    Oesophagitis
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    1 / 15 (6.67%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    Oral pain
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    1 / 15 (6.67%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    Proctalgia
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    1 / 18 (5.56%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    Tongue ulceration
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    1 / 15 (6.67%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    Salivary hypersecretion
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    0
    0
    0
    Abdominal pain upper
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 6 (16.67%)
    1 / 15 (6.67%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    1 / 36 (2.78%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    1
    2
    0
    0
    0
    0
    1
    0
    Hepatobiliary disorders
    Bile duct obstruction
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    1 / 15 (6.67%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    Hepatitis
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    Skin and subcutaneous tissue disorders
    Alopecia
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    2 / 3 (66.67%)
    2 / 3 (66.67%)
    4 / 6 (66.67%)
    3 / 15 (20.00%)
    22 / 55 (40.00%)
    8 / 14 (57.14%)
    4 / 15 (26.67%)
    7 / 15 (46.67%)
    19 / 36 (52.78%)
    6 / 18 (33.33%)
         occurrences all number
    0
    0
    0
    0
    0
    2
    2
    4
    3
    22
    8
    4
    7
    19
    6
    Pruritus
         subjects affected / exposed
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    1 / 3 (33.33%)
    0 / 6 (0.00%)
    3 / 15 (20.00%)
    10 / 55 (18.18%)
    2 / 14 (14.29%)
    2 / 15 (13.33%)
    1 / 15 (6.67%)
    6 / 36 (16.67%)
    1 / 18 (5.56%)
         occurrences all number
    1
    0
    0
    1
    0
    1
    1
    0
    5
    11
    3
    3
    1
    7
    1
    Rash
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    1 / 3 (33.33%)
    1 / 6 (16.67%)
    1 / 15 (6.67%)
    7 / 55 (12.73%)
    4 / 14 (28.57%)
    1 / 15 (6.67%)
    2 / 15 (13.33%)
    6 / 36 (16.67%)
    4 / 18 (22.22%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    1
    1
    2
    8
    4
    1
    2
    6
    5
    Dry skin
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    2 / 15 (13.33%)
    4 / 55 (7.27%)
    4 / 14 (28.57%)
    0 / 15 (0.00%)
    2 / 15 (13.33%)
    2 / 36 (5.56%)
    1 / 18 (5.56%)
         occurrences all number
    0
    0
    0
    2
    0
    0
    0
    0
    3
    4
    5
    0
    2
    2
    1
    Rash maculo-papular
         subjects affected / exposed
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    2 / 6 (33.33%)
    0 / 15 (0.00%)
    4 / 55 (7.27%)
    0 / 14 (0.00%)
    2 / 15 (13.33%)
    1 / 15 (6.67%)
    5 / 36 (13.89%)
    1 / 18 (5.56%)
         occurrences all number
    3
    0
    0
    0
    0
    0
    1
    2
    0
    4
    0
    2
    1
    6
    1
    Nail disorder
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    3 / 36 (8.33%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    3
    0
    Night sweats
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 6 (16.67%)
    0 / 15 (0.00%)
    3 / 55 (5.45%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    1
    0
    3
    0
    0
    0
    0
    0
    Acne
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    2 / 36 (5.56%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    2
    0
    Skin hyperpigmentation
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    1 / 14 (7.14%)
    0 / 15 (0.00%)
    1 / 15 (6.67%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    1
    0
    0
    Rash macular
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    1 / 18 (5.56%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    2
    Dermatitis
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    1 / 18 (5.56%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    Dermatitis acneiform
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    1 / 15 (6.67%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    Erythema
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    1 / 3 (33.33%)
    0 / 6 (0.00%)
    1 / 15 (6.67%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    1
    0
    1
    0
    0
    0
    0
    0
    0
    Hyperhidrosis
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    1 / 15 (6.67%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    Nail ridging
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    1 / 18 (5.56%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    Onycholysis
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    1 / 15 (6.67%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    Pain of skin
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    1 / 14 (7.14%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    Palmar-plantar erythrodysaesthesia syndrome
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    1 / 15 (6.67%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    Rash pruritic
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    1 / 15 (6.67%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    Skin ulcer
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    1 / 14 (7.14%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    Toxic skin eruption
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    1 / 14 (7.14%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    Urticaria
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    1 / 18 (5.56%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    Decubitus ulcer
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    Skin lesion
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    Renal and urinary disorders
    Renal pain
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    1 / 15 (6.67%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    1 / 18 (5.56%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    1
    Urine flow decreased
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    1 / 15 (6.67%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    Haematuria
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    2 / 6 (33.33%)
    3 / 15 (20.00%)
    5 / 55 (9.09%)
    1 / 14 (7.14%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    3 / 18 (16.67%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    0
    2
    3
    7
    2
    0
    0
    0
    4
    Proteinuria
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 6 (16.67%)
    0 / 15 (0.00%)
    1 / 55 (1.82%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    1
    0
    1
    0
    0
    0
    0
    0
    Urinary hesitation
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    Pollakiuria
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    2 / 55 (3.64%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    2
    0
    0
    0
    0
    0
    Renal impairment
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    1 / 15 (6.67%)
    0 / 36 (0.00%)
    1 / 18 (5.56%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    1
    Dysuria
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    1 / 14 (7.14%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    Hydronephrosis
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    1 / 15 (6.67%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    Musculoskeletal and connective tissue disorders
    Myalgia
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    3 / 15 (20.00%)
    5 / 55 (9.09%)
    0 / 14 (0.00%)
    2 / 15 (13.33%)
    1 / 15 (6.67%)
    9 / 36 (25.00%)
    5 / 18 (27.78%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    0
    0
    3
    6
    0
    2
    1
    9
    5
    Arthralgia
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    2 / 3 (66.67%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    2 / 3 (66.67%)
    0 / 6 (0.00%)
    1 / 15 (6.67%)
    6 / 55 (10.91%)
    2 / 14 (14.29%)
    0 / 15 (0.00%)
    2 / 15 (13.33%)
    6 / 36 (16.67%)
    4 / 18 (22.22%)
         occurrences all number
    0
    3
    0
    2
    0
    0
    2
    0
    1
    6
    2
    0
    2
    7
    5
    Back pain
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    2 / 6 (33.33%)
    1 / 15 (6.67%)
    6 / 55 (10.91%)
    2 / 14 (14.29%)
    1 / 15 (6.67%)
    2 / 15 (13.33%)
    3 / 36 (8.33%)
    5 / 18 (27.78%)
         occurrences all number
    0
    2
    0
    0
    0
    0
    0
    2
    3
    7
    2
    1
    2
    3
    5
    Pain in extremity
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    4 / 55 (7.27%)
    0 / 14 (0.00%)
    1 / 15 (6.67%)
    3 / 15 (20.00%)
    4 / 36 (11.11%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    1
    0
    0
    0
    7
    0
    1
    4
    5
    0
    Muscular weakness
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    3 / 55 (5.45%)
    1 / 14 (7.14%)
    2 / 15 (13.33%)
    1 / 15 (6.67%)
    2 / 36 (5.56%)
    2 / 18 (11.11%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    3
    1
    2
    2
    2
    2
    Musculoskeletal pain
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 6 (16.67%)
    1 / 15 (6.67%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    1 / 15 (6.67%)
    2 / 36 (5.56%)
    1 / 18 (5.56%)
         occurrences all number
    0
    1
    1
    0
    0
    0
    0
    1
    2
    0
    0
    0
    1
    2
    1
    Muscle spasms
         subjects affected / exposed
    0 / 3 (0.00%)
    2 / 3 (66.67%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    2 / 15 (13.33%)
    2 / 36 (5.56%)
    0 / 18 (0.00%)
         occurrences all number
    0
    2
    1
    0
    0
    0
    0
    0
    0
    0
    0
    0
    3
    2
    0
    Musculoskeletal chest pain
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    1 / 15 (6.67%)
    0 / 15 (0.00%)
    2 / 36 (5.56%)
    1 / 18 (5.56%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    2
    0
    2
    1
    Bone pain
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    2 / 14 (14.29%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    0
    0
    0
    0
    2
    0
    0
    0
    0
    Flank pain
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    1 / 15 (6.67%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    2
    0
    0
    Bursitis
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    1 / 18 (5.56%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    Muscle atrophy
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    1 / 15 (6.67%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    Musculoskeletal stiffness
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 6 (16.67%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    1 / 18 (5.56%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    1
    Arthritis climacteric
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    Joint swelling
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    Tendonitis
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    Infections and infestations
    Conjunctivitis
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    2 / 3 (66.67%)
    0 / 3 (0.00%)
    1 / 6 (16.67%)
    7 / 15 (46.67%)
    23 / 55 (41.82%)
    6 / 14 (42.86%)
    4 / 15 (26.67%)
    6 / 15 (40.00%)
    15 / 36 (41.67%)
    9 / 18 (50.00%)
         occurrences all number
    0
    0
    0
    0
    0
    2
    0
    1
    9
    37
    8
    5
    7
    19
    9
    Urinary tract infection
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    2 / 6 (33.33%)
    2 / 15 (13.33%)
    11 / 55 (20.00%)
    0 / 14 (0.00%)
    1 / 15 (6.67%)
    0 / 15 (0.00%)
    4 / 36 (11.11%)
    1 / 18 (5.56%)
         occurrences all number
    0
    0
    0
    1
    2
    0
    0
    3
    3
    16
    0
    1
    0
    6
    1
    Nasopharyngitis
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    2 / 15 (13.33%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    1 / 15 (6.67%)
    3 / 36 (8.33%)
    2 / 18 (11.11%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    2
    0
    0
    0
    1
    3
    2
    Oral herpes
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    3 / 55 (5.45%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    4 / 36 (11.11%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    3
    0
    0
    0
    4
    0
    Upper respiratory tract infection
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 6 (16.67%)
    1 / 15 (6.67%)
    0 / 55 (0.00%)
    3 / 14 (21.43%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    2 / 36 (5.56%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    0
    1
    1
    0
    3
    0
    0
    3
    0
    Oral candidiasis
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    1 / 15 (6.67%)
    3 / 55 (5.45%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    1 / 15 (6.67%)
    0 / 36 (0.00%)
    1 / 18 (5.56%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    3
    0
    0
    1
    0
    1
    Sinusitis
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    1 / 15 (6.67%)
    3 / 36 (8.33%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    1
    0
    0
    0
    0
    0
    0
    1
    3
    0
    Lower respiratory tract infection
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    1 / 15 (6.67%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    2 / 15 (13.33%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    2
    0
    0
    Rash pustular
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    3 / 15 (20.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    3
    0
    0
    0
    0
    0
    0
    Influenza
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    1 / 14 (7.14%)
    0 / 15 (0.00%)
    1 / 15 (6.67%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    1
    0
    0
    Bronchitis
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    1 / 18 (5.56%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    Candida infection
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    1 / 15 (6.67%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    Catheter site infection
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    1 / 15 (6.67%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    Conjunctivitis bacterial
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    1 / 18 (5.56%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    Cystitis
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    1 / 14 (7.14%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    Eye infection
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    1 / 15 (6.67%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    Gingivitis
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    1 / 15 (6.67%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    Haemophilus infection
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    1 / 15 (6.67%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    Skin infection
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    1 / 18 (5.56%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    Tooth abscess
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    1 / 15 (6.67%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    Cellulitis
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    1 / 3 (33.33%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    1
    0
    0
    0
    0
    0
    0
    0
    0
    Pneumonia
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    0
    0
    Gastroenteritis
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    Urethritis
         subjects affected / exposed
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    Metabolism and nutrition disorders
    Decreased appetite
         subjects affected / exposed
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    5 / 6 (83.33%)
    3 / 15 (20.00%)
    20 / 55 (36.36%)
    5 / 14 (35.71%)
    6 / 15 (40.00%)
    5 / 15 (33.33%)
    12 / 36 (33.33%)
    10 / 18 (55.56%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    1
    5
    3
    22
    6
    7
    5
    13
    14
    Hypokalaemia
         subjects affected / exposed
    0 / 3 (0.00%)
    2 / 3 (66.67%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    2 / 6 (33.33%)
    2 / 15 (13.33%)
    11 / 55 (20.00%)
    1 / 14 (7.14%)
    2 / 15 (13.33%)
    2 / 15 (13.33%)
    5 / 36 (13.89%)
    2 / 18 (11.11%)
         occurrences all number
    0
    2
    0
    0
    0
    0
    1
    2
    2
    14
    2
    2
    2
    6
    3
    Hypomagnesaemia
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 6 (16.67%)
    0 / 15 (0.00%)
    6 / 55 (10.91%)
    1 / 14 (7.14%)
    2 / 15 (13.33%)
    0 / 15 (0.00%)
    4 / 36 (11.11%)
    1 / 18 (5.56%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    1
    0
    6
    1
    3
    0
    4
    1
    Dehydration
         subjects affected / exposed
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 6 (16.67%)
    1 / 15 (6.67%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    2 / 15 (13.33%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    1 / 18 (5.56%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    1
    1
    0
    0
    2
    0
    0
    1
    Hyponatraemia
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    2 / 15 (13.33%)
    0 / 55 (0.00%)
    1 / 14 (7.14%)
    1 / 15 (6.67%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    2
    0
    1
    1
    0
    0
    0
    Hyperglycaemia
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 6 (16.67%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    1 / 15 (6.67%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    1 / 18 (5.56%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    2
    0
    0
    0
    1
    0
    0
    1
    Hypocalcaemia
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    1 / 15 (6.67%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    1 / 18 (5.56%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    1
    Hyperuricaemia
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    1 / 14 (7.14%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    Hypoalbuminaemia
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    1 / 15 (6.67%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    Hypophosphataemia
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    1 / 15 (6.67%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    0
    0
    0
    Iron deficiency
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    1 / 15 (6.67%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    Vitamin d deficiency
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    1 / 15 (6.67%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    0
    1
    0
    0
    0
    Hyperkalaemia
         subjects affected / exposed
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    2 / 55 (3.64%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    1
    0
    0
    3
    0
    0
    0
    0
    0
    Hypercalcaemia
         subjects affected / exposed
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    0 / 3 (0.00%)
    1 / 3 (33.33%)
    0 / 6 (0.00%)
    0 / 15 (0.00%)
    0 / 55 (0.00%)
    0 / 14 (0.00%)
    0 / 15 (0.00%)
    0 / 15 (0.00%)
    0 / 36 (0.00%)
    0 / 18 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    2
    0
    0
    0
    0
    0
    0
    0
    0

    More information

    		 Close Top of page

    Substantial protocol amendments (globally)
    Were there any global substantial amendments to the protocol? Yes
    Date
    Amendment
    05 Sep 2013
    The following updates were made: • Revisions made in accordance with questions raised by the UK Medicines and Healthcare products Regulatory Agency and the United States FDA. • Revised inclusion criterion to exclude subjects with platinum-sensitive ovarian cancer from the Expansion Part of the trial. • Revised inclusion criterion to ensure that subjects with metastatic castration resistant prostate cancer had received abiraterone and/or enzalutamide prior to entering the Expansion Part. • Specified plan for assessing human anti-human antibodies to both antibody-drug conjugate and total antibody and plan for evaluating the impact of immunogenicity on PK, activity and safety of tisotumab vedotin. • Visual acuity assessment was added. • Communication plan on how the assignment of subjects to a cohort was undertaken was added. • Criteria for subject withdrawal from treatment were modified. • A list of strong CYP3A4 inhibitors was added. • Investigators were to consult an ophthalmologist for any subject experiencing clinical significant ophthalmologic AEs. • Dose Escalation rules were updated. • Dose level toxicity definitions were updated. • Details on post-infusion monitoring were added. • Clarified that the CTCAE grade of all bleeding AEs were to be reported.
    28 Jan 2014
    The following update was made: • Updated in response to the Danish Competent Authority request to specify the contraceptive measures, and comments from a US site Clinical Review Committee to clarify trial-related procedures and further define research endpoints.
    03 Apr 2014
    The following update was made: • Exclusion criterion modified such that subjects requiring IV treatment with antimicrobial therapy starting less than 4 weeks prior to first dose or oral treatment with antimicrobial therapy starting less than 2 weeks prior to first dose were excluded.
    05 May 2014
    The following update was made: • Modified due to an event of pharyngeal tumor hemorrhage with fatal outcome. The DMC recommended exclusion of subjects with squamous cell carcinoma of the head and neck from the Dose Escalation Part.
    12 Sep 2014
    The following update was made: • Revised inclusion criterion with respect to coagulation status.
    29 May 2015
    The following updates were made: • Trial phase changed from I to I/II to reflect that only the Dose Escalation Part was first-in-human, and the Expansion Part was phase II. • Updated the Expansion Part of the trial including clarification of the approach for the types of cancers that were included, and an increase of subjects to be enrolled.
    23 Nov 2015
    The following updates were made: • Updated to encompass adaptive changes based on biomarker-derived data. • Prespecified 2 of the trial cohorts for Expansion Part, endometrial and cervical cancer. • Increased the planned number of subjects in the Expansion Part. • Aligned the treatment guidelines in the US and EU.
    17 Mar 2016
    The following updates were made: • In order to better describe safety and preliminary biological activity signals, a cap on previous exposure to anticancer therapies for subjects to be included in the Expansion Part was introduced in this amendment. • Requirements for tumor biopsies in the Expansion Part were changed so archived samples, if available, could be used. • Pregnancy tests were added for women of childbearing potential in accordance with the “Recommendations related to contraception and pregnancy testing in clinical trials” of the Clinical Trial Facilitation Group.
    03 Jun 2016
    The following updates were made: • Clarified that the sponsor made every effort to ensure that the principles of GCP will be set in place for the exploratory analysis of protein biomarkers. • Specified the defined limit for human exposure of tisotumab vedotin and free toxin MMAE. • Clarified that all investigators received the suspected unexpected serious adverse reaction reports. • Explained that in case of potential serious breach, these were reported to the competent authorities immediately.
    07 Jul 2016
    The following updates were made: • Updated with safety information concerning ocular events (conjunctivitis). • Inclusion criterion on acceptable hematological status was modified. • A 40-day wash-out period combined with a requirement for no residual check point related symptoms of autoimmune toxicity was added.
    27 Oct 2016
    The following updates were made: • Modified the evaluation and mitigation plan for ocular events. • Some inclusion and exclusion criteria were reworded for clarification and/or to adapt to current experience or standard practice. • In the Expansion Part the wording was modified regarding the number of subjects per cohort (fixed at 14 subjects) and the conditions to expand to 30 subjects to maintain flexibility to expand the cohorts with the most promising benefit/risk ratios. • The number of participating sites for the Expansion Part was increased.
    22 Dec 2016
    The following updates were made: • One CTCAE grade 3 event of conjunctivitis had already been reported in the GEN702 trial. Following the cutoff date of 31 May 2016, 3 additional CTCAE grade 3 events of conjunctivitis and one CTCAE grade 4 event of keratitis had been reported. The purpose of the amendment was to update this information in the protocol and to modify the dose modification and mitigation plans for ocular events accordingly, including mandatory preventive eye therapy.
    26 Sep 2017
    The following updates were made: • Modified to allow recruitment of up to 25 additional subjects with cervical cancer for a maximum of approximately 55 subjects. • Updated the clinical experience and risks to human subjects based on relevant experience in ongoing trials. • Clarified the evaluation and mitigation plan for ocular events.
    05 Oct 2017
    The following update was made: • Modified the inclusion/exclusion criteria to allow subjects on stable doses of anticoagulation therapy for ≥8 weeks to enter the trial.

    Interruptions (globally)
    Were there any global interruptions to the trial? No

    Limitations and caveats
    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Apr 26 00:01:37 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA